Table of Contents

• Trial overview
• Who the study is for
• What the study measures
• Trial phase and design
• What the results may mean

Trial overview

The listed study is a clinical trial of HLX43 in people with advanced non-small cell lung cancer (NSCLC).^[1] It is an interventional study, which means researchers give the study treatment and then measure what happens.^[1]

The trial title says it is a global safety and effectiveness study, and the brief summary says it aims to evaluate the clinical efficacy of HLX43 in advanced NSCLC.^[1]

Who the study is for

This trial is for people with advanced non-small cell lung cancer (NSCLC).^[1] The source data does not list more detailed entry rules, such as age limits or prior treatments, so those details are not available here.^[1]

The study plans to enroll 243 participants, which means up to 243 people are expected to join if they meet the study rules.^[1]

What the study measures

The main outcome is objective response rate (ORR).^[1] ORR shows how many people have a measurable cancer response, such as the tumor getting smaller, based on scan review.^[1]

The study uses Blinded Independent Central Review (BICR) and RECIST v1.1 to assess the response.^[1] BICR means independent reviewers look at the scans without knowing which treatment was given, and RECIST v1.1 is a standard system for measuring tumor changes.^[1]

Trial phase and design

The study is in Phase 2.^[1] Phase 2 trials usually focus on whether a treatment may work in a specific disease while continuing to collect safety information.^[1]

The trial status is listed as Authorised.^[1] This means the study has been approved to proceed according to the source data.^[1]

The intervention is listed as HLX43 for Injection given by intravenous administration, which means it is given through a vein.^[1]

What the results may mean

This trial is designed to show whether HLX43 can produce a measurable cancer response in advanced NSCLC.^[1] Because the study is still in Phase 2, it is part of the process of learning more about the treatment in a defined patient group.^[1]

The available data does not report study results yet, so the article can only describe the trial plan, not the outcome.^[1]

Table of Contents

• Trial overview
• Who participated
• What was measured
• Study design and phase
• Condition focus: Crohn’s disease

Trial overview

This article covers one clinical trial of VERCIRNON, identified as 2022-502843-36-00, which was a completed Phase 1 interventional study.^[1] The study used a PET scan approach to examine where the radiotracer [11C]AZ14132516 goes in the body after VERCIRNON was given.^[1]

Who participated

The trial enrolled 9 healthy participants.^[1] Even though the participants were healthy, the study was linked to Crohn’s disease research because the condition was listed in the trial data.^[1]

What was measured

The main results were standard uptake value (SUV) and standard uptake value ratio (SUVR) in regions of interest.^[1] These scan measures help show how much tracer is taken up and how much total binding occurs to CCR9 in the body areas being studied.^[1]

The brief summary says the study aimed to examine the distribution of [11C]AZ14132516 and its binding to CCR9 in anatomical regions of interest in the abdominal area.^[1] In simple words, researchers wanted to see where the tracer traveled and how it behaved in the belly area on the scan.^[1]

Study design and phase

This was an interventional study, which means researchers gave the study intervention and then observed the results.^[1] It was in Phase 1, the earliest stage of clinical research, which is often used to gather first information about how a study test performs in people.^[1]

Condition focus: Crohn’s disease

The only condition named in the source data was Crohn’s disease.^[1] The trial did not describe treatment of symptoms; instead, it focused on imaging and binding measurements that may help researchers study this condition in the abdominal area.^[1]

Table of contents

• Trial overview
• Study design and phase
• Who can participate
• What is being measured
• Why this trial matters

Trial overview

The available clinical trial data describe one study, the ELIPS-Trial, which is testing HUMAN PLASMA in patients with haemorrhagic shock.^[1] The study is authorised and is being run as an interventional trial, which means researchers are giving a treatment and then measuring the results.^[1]

This trial compares early administration of lyophilized plasma with conventional crystalloid infusion solutions in the emergency room.^[1] The study team wants to know if earlier plasma use can help patients stabilize faster after major blood loss.^[1]

Study design and phase

The ELIPS-Trial is a Phase 3 study with an enrollment of 30 participants.^[1] Phase 3 studies usually test whether a treatment works well in a larger patient group and compare it with standard care.^[1]

In this trial, the intervention listed for HUMAN PLASMA is LyoPlas N – W, which is a lyophilized, or freeze-dried, plasma product.^[1] The comparison treatment is ELO-MEL isoton, a crystalloid infusion solution used as conventional fluid therapy.^[1]

Who can participate

The target population is patients with haemorrhagic shock who are treated in the emergency room.^[1] The source data do not give more detailed inclusion or exclusion rules, so the main known requirement is the presence of this emergency condition.^[1]

Haemorrhagic shock means the body has lost a large amount of blood and may not be getting enough blood flow to vital organs.^[1] This is a medical emergency, which is why the trial focuses on treatment started very early in care.^[1]

What is being measured

The brief summary says the study expects faster hemodynamic stabilization, which means better blood pressure and circulation stability.^[1] It also uses normalization of lactate levels to below 2 mmol/L as a surrogate parameter, meaning an indirect sign of recovery.^[1]

The trial also looks at whether HUMAN PLASMA can reduce the amount of crystalloid infusion solutions needed.^[1] The study team believes this may help avoid volume overload, which means too much fluid in the body.^[1]

The summary also states that lyophilized plasma may be faster to give than conventional plasma, with an application time of about 6.5 minutes versus about 30 to 45 minutes for conventional plasma.^[1] The trial uses this practical advantage as part of its research question in emergency treatment.^[1]

Why this trial matters

This study is important because haemorrhagic shock needs very fast treatment, and delays can be dangerous.^[1] The trial is designed to see whether a plasma-based approach can support quicker stabilization than standard fluid therapy.^[1]

For patients and families, the key point is that the research is not about long-term routine use, but about emergency care in a life-threatening situation.^[1] The goal is to find a better early treatment strategy for severe blood loss in the emergency room.^[1]

Table of contents

• Trial overview
• Who can participate
• What is being studied
• What outcomes are measured
• Trial phase and status
• Key patient terms

Trial overview

The available trial is a first-in-human study, which means it is the first time this approach is being tested in people.^[1] It is designed to study the safety and preliminary efficacy of expanded autologous urothelial cells bioprinted during orthotopic neobladder surgery.^[1]

The study is interventional, so the research team gives the study procedure as part of the trial instead of only observing patients.^[1] The planned enrollment is 6 patients.^[1]

Who can participate

The trial is for patients with muscle-invasive bladder cancer (MIBC) who are eligible for neobladder reconstruction after radical cystectomy.^[1] Radical cystectomy means surgery to remove the bladder.^[1]

This means the study is focused on a very specific group of people who are already planned for major bladder surgery and may receive a new bladder, called an orthotopic neobladder.^[1]

What is being studied

The trial is studying AUROCELL-TX, listed in the source as aUroCell-Tx, used with the InvivoLPrint-U bioprinter during neobladder surgery.^[1] A bioprinter is a device that places living cells in a planned shape or structure for medical use.^[1]

The study summary says the goal is to evaluate the safety of the expanded autologous urothelial cells and the bioprinter combination in the surgical setting.^[1] In simple terms, researchers want to see whether this approach can be used safely during surgery and whether there are early signs that it may help.^[1]

What outcomes are measured

The main outcomes focus on safety after surgery.^[1] These include the proportion of patients with a fatal event (death), neobladder rejection, and the need for revision surgery.^[1]

The trial also measures the proportion of patients who are free from the combined endpoint of death, neobladder rejection, and need for revision surgery.^[1] A composite endpoint is one result that combines several important events into a single measure.^[1]

Researchers will also record peri- and post-surgical complications and serious adverse events (SAEs).^[1] These are important because they show what problems happen during surgery and in the recovery period.^[1]

Trial phase and status

This is a Phase 1 trial.^[1] Phase 1 studies are early trials that mainly look at safety and how the study approach performs in a small number of people.^[1]

The study status is Authorised.^[1] That means the trial has been approved to move forward.^[1]

Key patient terms

Autologous means the cells come from the same person who will receive them.^[1] This is important because the trial is using the patient’s own urothelial cells.^[1]

Urothelial cells are cells that line the inside of the urinary tract, including the bladder.^[1] Orthotopic neobladder means a new bladder made during surgery and placed in the usual bladder position.^[1]

Revision surgery means another operation is needed to fix or adjust the first surgery result.^[1] Peri-surgical means around the time of surgery, and post-surgical means after surgery.^[1]

Table of Contents

• What is [18F]FLUORO-PEG-FOLATE?
• How Does [18F]FLUORO-PEG-FOLATE Work?
• Medical Conditions Being Studied
• Potential Benefits
• How is [18F]FLUORO-PEG-FOLATE Administered?
• Ongoing Research and Clinical Trials

What is [18F]FLUORO-PEG-FOLATE?

[18F]FLUORO-PEG-FOLATE, also known as [18F]Fluor-PEG-Folate, is a novel imaging agent used in positron emission tomography (PET) scans. It is not a medication to treat diseases, but rather a tool to help doctors visualize and measure inflammation in the body^[1]. This substance is currently being studied for its potential to improve the diagnosis and monitoring of various inflammatory conditions, particularly rheumatoid arthritis.

How Does [18F]FLUORO-PEG-FOLATE Work?

[18F]FLUORO-PEG-FOLATE works by targeting specific cells in the body called macrophages, which are a type of white blood cell involved in inflammation. When injected into the body, this substance binds to receptors on these macrophages, allowing them to be visible on PET scans^[1]. This helps doctors see where inflammation is occurring in the body, even before symptoms may be noticeable.

Medical Conditions Being Studied

Currently, [18F]FLUORO-PEG-FOLATE is being researched for use in several inflammatory conditions:

• Rheumatoid Arthritis (RA): This is a chronic inflammatory disorder that primarily affects the small joints of the hands and feet^[1].
• ACPA-positive arthralgia: This condition refers to joint pain in individuals who have tested positive for certain antibodies (anti-citrullinated protein antibodies or ACPA) associated with RA, but have not yet developed full-blown arthritis^[2].
• Giant Cell Arteritis (GCA): This is an inflammatory disease of blood vessels, primarily affecting the arteries in the head and neck^[3].

Potential Benefits

The use of [18F]FLUORO-PEG-FOLATE in PET scans may offer several potential benefits:

• Early detection: It may help identify inflammation before symptoms become severe, potentially allowing for earlier treatment^[2].
• Monitoring treatment response: Doctors may use it to see how well treatments are working by comparing scans before and after therapy^[1].
• Predicting disease progression: In conditions like ACPA-positive arthralgia, it might help predict who is likely to develop full RA^[2].
• Guiding treatment decisions: The scans could help doctors decide when to start or change treatments^[1][3].

How is [18F]FLUORO-PEG-FOLATE Administered?

[18F]FLUORO-PEG-FOLATE is given as an intravenous injection, meaning it’s delivered directly into a vein. The dose can vary depending on the specific study, but typically ranges from about 200 to 400 MBq (megabecquerels, a unit of radioactivity)^[1][3]. After the injection, patients undergo a PET/CT scan, which combines the PET images with CT (computed tomography) images to provide detailed pictures of the body.

Ongoing Research and Clinical Trials

Several clinical trials are currently underway to evaluate the effectiveness of [18F]FLUORO-PEG-FOLATE PET imaging:

1. Rheumatoid Arthritis Study: This trial is investigating how well [18F]FLUORO-PEG-FOLATE PET/CT can monitor response to anti-TNF therapy in patients with active RA^[1].
2. ACPA-positive Arthralgia Study: This study aims to determine if [18F]FLUORO-PEG-FOLATE PET/CT can predict which patients with ACPA-positive arthralgia will develop clinical arthritis within one year^[2].
3. Giant Cell Arteritis Study: This pilot study is evaluating the use of [18F]FLUORO-PEG-FOLATE PET/CT in patients with active, large vessel GCA, both before and after treatment^[3].

These studies will help determine the full potential of [18F]FLUORO-PEG-FOLATE as a diagnostic and monitoring tool for inflammatory conditions. As research progresses, this imaging technique may become an important part of managing these diseases in the future.

Table of Contents

• Overview of [18F]MC225 Clinical Research
• Understanding P-glycoprotein Function
• Clinical Trial in Treatment-Resistant Depression
• Clinical Trial in Neurodegenerative Diseases
• How [18F]MC225 is Administered
• What the Trials are Measuring

Overview of [18F]MC225 Clinical Research

[18F]MC225 is a radiotracer being investigated in clinical trials for its ability to measure P-glycoprotein (P-gp) function in the brain using PET/CT imaging. Currently, two Phase 2 clinical trials have been authorized to study this imaging agent in different patient populations^[1][2].

The chemical name of [18F]MC225 is 5-(1-(2-[18F]fluoroethoxy))-[3-(6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl)-propyl]-5,6,7,8-tetrahydronaphthalen. This compound is labeled with fluorine-18, a radioactive isotope that allows it to be detected by PET scanners^[2].

These clinical trials represent important research efforts to understand how P-glycoprotein activity may be altered in various brain disorders. The trials are investigating both psychiatric conditions, specifically treatment-resistant depression, and neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, and mild cognitive impairment^[1][2].

Understanding P-glycoprotein Function

P-glycoprotein is a protein that functions as a transporter in cell membranes throughout the body, with particularly important roles at the blood-brain barrier. This barrier is a protective system that controls which substances can enter brain tissue from the bloodstream.

P-gp acts as an efflux pump, meaning it actively pumps certain substances out of cells and prevents them from entering the brain. This mechanism serves several important functions:

• Protection: P-gp helps protect the brain from potentially toxic compounds by preventing their entry into brain tissue
• Drug transport: P-gp can affect how medications reach the brain, which may influence treatment effectiveness
• Disease involvement: Changes in P-gp function have been linked to various neurological and psychiatric conditions

Understanding P-gp activity in different disease states may help explain why some patients respond to treatments while others do not, and could lead to better therapeutic approaches.

Clinical Trial in Treatment-Resistant Depression

The first authorized trial (2023-508303-20-01) is investigating the role of P-glycoprotein in treatment-resistant depression (TRD). This Phase 2 interventional study plans to enroll 44 participants^[1].

The primary aim of this study is to assess the involvement of P-gp in TRD by comparing P-gp activity between two groups of patients:

• Subjects with treatment-resistant depression: Patients whose depression has not responded adequately to standard antidepressant treatments
• Subjects with treatment-responsive depression (DRESP): Patients whose depression has responded well to antidepressant medications

The study uses [18F]MC225 PET/CT imaging to measure P-gp activity in the brain. The hypothesis behind this research is that differences in P-gp function may explain why some patients respond to antidepressant medications while others do not^[1].

If P-gp is more active in patients with treatment-resistant depression, it might be pumping antidepressant medications out of the brain before they can have their therapeutic effect. This would represent an important mechanism of treatment resistance and could point to new therapeutic strategies.

Clinical Trial in Neurodegenerative Diseases

The second authorized trial (2024-518865-85-00) is evaluating [18F]MC225 to measure P-glycoprotein function in patients with neurodegenerative diseases. This Phase 2 study plans to enroll 30 participants^[2].

The trial is investigating three related neurodegenerative conditions:

• Alzheimer’s disease: A progressive brain disorder that causes memory loss and cognitive decline, characterized by the buildup of abnormal proteins in the brain
• Mild Cognitive Impairment (MCI): A condition involving noticeable decline in cognitive abilities that is greater than expected for age but not severe enough to interfere significantly with daily activities; MCI may progress to Alzheimer’s disease
• Parkinson’s disease: A progressive disorder affecting movement and coordination, caused by loss of nerve cells in specific brain regions

Changes in P-glycoprotein function have been observed in neurodegenerative diseases and may contribute to disease progression. P-gp alterations could affect the accumulation of toxic proteins in the brain or influence how medications used to treat these conditions reach their targets^[2].

This trial aims to characterize P-gp function across these different neurodegenerative conditions, which may help researchers understand disease mechanisms and develop better treatments.

How [18F]MC225 is Administered

[18F]MC225 is administered as an intravenous injection, meaning it is injected directly into a vein. The dose used in the clinical trial for neurodegenerative diseases is 400 MBq (megabecquerel), which is a unit measuring radioactivity^[2].

The administration process typically involves the following steps:

• Preparation: The radiotracer is prepared in a specialized facility and must be used within a short time frame due to the radioactive decay of fluorine-18
• Injection: The [18F]MC225 solution is injected intravenously, usually into an arm vein
• Distribution: After injection, the radiotracer circulates through the bloodstream and crosses into the brain
• Imaging: PET/CT scanning is performed to detect where the radiotracer accumulates in the brain

The amount of radiation exposure from [18F]MC225 is comparable to other diagnostic nuclear medicine procedures and is considered safe for research purposes when appropriate safety protocols are followed.

What the Trials are Measuring

Both clinical trials use specialized imaging measurements to assess P-glycoprotein function in the brain. These measurements provide quantitative data about how [18F]MC225 is distributed in brain tissue.

The trial in treatment-resistant depression is measuring P-gp activity by assessing [18F]MC225 standardized uptake value (SUV) and volume distribution (VD) in the whole brain. SUV is a measurement that indicates how much radiotracer has accumulated in brain tissue, while volume distribution describes how the tracer spreads throughout the brain^[1].

The trial in neurodegenerative diseases is measuring regional PET tracer uptake and influx values of [18F]MC225. This approach examines specific brain regions rather than the whole brain, which may reveal regional differences in P-gp function that are relevant to different neurodegenerative diseases^[2].

Key measurements being assessed include:

• Uptake values: How much [18F]MC225 accumulates in different brain regions, which reflects P-gp activity (higher uptake may indicate lower P-gp activity, as less tracer is being pumped out)
• Influx values: The rate at which [18F]MC225 enters brain tissue from the bloodstream
• Regional patterns: Differences in tracer distribution across various brain areas, which may correlate with disease-specific patterns
• Comparison between groups: Differences in measurements between patients with different conditions or treatment responses

These measurements will help researchers understand whether P-glycoprotein function is altered in treatment-resistant depression and neurodegenerative diseases, and whether these alterations follow specific patterns that could be clinically meaningful.

The data collected from these Phase 2 trials will be important for determining whether [18F]MC225 PET imaging can serve as a useful tool for understanding disease mechanisms, predicting treatment responses, or monitoring disease progression in these conditions.

Table of Contents

• What is [18F]META-FLUOROBENZYLGUANIDINE?
• Medical Conditions [18F]mFBG Can Help Diagnose
• How [18F]mFBG Works
• Advantages of [18F]mFBG PET-CT
• Current Clinical Trials
• Safety Considerations

What is [18F]META-FLUOROBENZYLGUANIDINE?

[18F]META-FLUOROBENZYLGUANIDINE, also known as [18F]mFBG, is a diagnostic tool used in medical imaging^[1]. It is a radioactive tracer that is injected into the body to help doctors see certain types of tumors more clearly. This substance is given as a solution for injection and is used in combination with a special type of imaging called PET-CT (Positron Emission Tomography-Computed Tomography)^[2].

It’s important to note that [18F]mFBG has several other names that you might hear doctors or researchers use. These include:

• Florbenguane (18F)
• IRP-101
• 1-(3-(fluoro-18F)benzyl)guanidine

Medical Conditions [18F]mFBG Can Help Diagnose

[18F]mFBG is being studied for its ability to help diagnose two main types of tumors:

1. Neuroblastoma: This is a type of cancer that develops from immature nerve cells. It most commonly affects children^[1].
2. Pheochromocytoma: This is a rare tumor that develops in the adrenal glands, which are located on top of the kidneys. These tumors can cause the body to produce too many hormones, leading to various symptoms^[2].

How [18F]mFBG Works

[18F]mFBG works by targeting specific features of these tumors. When injected into the body, it attaches to something called the norepinephrine transporter, which is found in high levels in neuroblastoma and pheochromocytoma cells^[2]. This allows the tumors to “light up” on the PET-CT scan, making them easier for doctors to see and diagnose.

Advantages of [18F]mFBG PET-CT

Researchers are studying [18F]mFBG because it may offer several advantages over current diagnostic methods:

• Improved detection: It may be better at finding both skeletal lesions (tumors in bones) and soft tissue lesions compared to the current standard method ([123I]mIBG scanning)^[1].
• Faster results: The PET-CT scan with [18F]mFBG can potentially be done more quickly than current methods^[1].
• More detailed images: PET-CT scans generally provide more detailed images than other types of scans, which could help doctors make more accurate diagnoses^[2].

Current Clinical Trials

As of now, [18F]mFBG is being studied in clinical trials to determine how well it works compared to current diagnostic methods. Two main studies are ongoing:

1. A study comparing [18F]mFBG PET-CT to [123I]mIBG scanning in patients with neuroblastoma^[1].
2. A study using [18F]mFBG PET-CT to image pheochromocytoma^[2].

These studies aim to determine how accurate [18F]mFBG is in detecting tumors, the best timing for the scans, and how safe it is to use in patients.

Safety Considerations

As with any medical procedure, there are some safety considerations to keep in mind:

• [18F]mFBG is radioactive, so the amount used is carefully controlled to minimize radiation exposure^[1].
• It cannot be used in pregnant or breastfeeding women^[2].
• Researchers are carefully monitoring for any side effects or adverse reactions in the clinical trials^[2].

It’s important to remember that [18F]mFBG is still being studied and is not yet approved for general use. If you or a loved one has been diagnosed with neuroblastoma or pheochromocytoma, talk to your doctor about the best diagnostic options for your specific situation.

Table of Contents

• Overview of Clinical Trials
• What the Trials Are Studying
• Imaging Technology Used
• Primary Trial Objectives
• Patient Population and Enrollment
• Potential Clinical Applications

Overview of Clinical Trials

Clinical research is currently underway to investigate [68Ga]GA-NOTA-AE105 as an imaging tracer for patients with gliomas, which are tumors that develop in the brain and spinal cord^[1]. The ongoing Phase 1 trial, registered as NCT02945826, has been authorized and has enrolled 61 patients to evaluate this novel imaging approach^[1]. This interventional study represents an important step in developing better diagnostic tools for brain tumor patients.

The tracer [68Ga]GA-NOTA-AE105 is designed to bind to a protein called uPAR (urokinase-type plasminogen activator receptor), which is often found in higher amounts on cancer cells^[1]. By attaching a radioactive marker to a molecule that seeks out uPAR, researchers hope to create images that show exactly where tumor cells are located and how aggressive they might be.

What the Trials Are Studying

The clinical trial investigating [68Ga]GA-NOTA-AE105 focuses on several important research questions related to brain tumor imaging and diagnosis^[1]. These objectives aim to improve how doctors diagnose, monitor, and treat patients with gliomas.

Visualization of Gliomas

One of the primary goals is to determine whether uPAR-PET imaging with [68Ga]GA-NOTA-AE105 can effectively visualize gliomas^[1]. Researchers are examining whether the amount of tracer that accumulates in the tumor on imaging scans directly corresponds to the actual amount of uPAR protein present in the tumor tissue^[1]. To verify this relationship, the study compares imaging results with immunohistochemical analysis of tumor tissue samples obtained through stereotactic biopsies or during surgical procedures^[1].

Tumor Grade Differentiation

Another key objective is to evaluate whether [68Ga]GA-NOTA-AE105 imaging can distinguish between high-grade gliomas and low-grade gliomas^[1]. High-grade gliomas are more aggressive and fast-growing tumors, while low-grade gliomas tend to grow more slowly. The hypothesis is that these different tumor types express different levels of uPAR protein, which would result in different amounts of tracer uptake visible on PET scans^[1]. If successful, this could help doctors determine tumor aggressiveness without always needing invasive biopsies.

Distinguishing Recurrence from Treatment Effects

A particularly challenging clinical problem that this trial addresses is differentiating between actual tumor progression or recurrence and post-therapeutic effects^[1]. After treatments like radiation therapy or chemotherapy, brain tissue can show changes on standard imaging that look similar to tumor growth, making it difficult for doctors to know whether the cancer has returned or if they are seeing treatment-related changes. The study investigates whether [68Ga]GA-NOTA-AE105 can help solve this problem by showing different uptake patterns based on varying levels of uPAR expression between true tumor tissue and treatment-related changes^[1].

Survival Prediction

The trial also examines whether high uptake of [68Ga]GA-NOTA-AE105 in brain tumors is associated with shorter survival times for patients^[1]. If higher tracer uptake correlates with worse outcomes, this imaging technique could potentially help doctors predict prognosis and tailor treatment strategies accordingly. This prognostic information could be valuable for treatment planning and for informing patients about their expected outcomes.

Imaging Technology Used

The clinical trial utilizes advanced imaging technologies, specifically uPAR-PET/MR and uPAR-PET/CT scanning^[1]. These hybrid imaging approaches combine different imaging modalities to provide comprehensive information about brain tumors.

PET/MRI Imaging

PET/MRI combines positron emission tomography with magnetic resonance imaging^[1]. The PET component shows the metabolic activity and tracer uptake in the tumor, while the MRI provides detailed anatomical images of brain structures. This combination offers excellent soft tissue contrast, which is particularly important for brain imaging, along with functional information about tumor biology.

PET/CT Imaging

PET/CT combines positron emission tomography with computed tomography scanning^[1]. This approach provides both functional information from the PET scan and anatomical detail from the CT scan. While CT does not provide the same soft tissue contrast as MRI, PET/CT is widely available and offers faster scanning times, making it a practical option for many patients.

How the Tracer Works

The tracer [68Ga]GA-NOTA-AE105 consists of a targeting molecule (AE105) that binds specifically to uPAR, attached to a radioactive isotope (Gallium-68) through a chemical linker (NOTA)^[1]. When injected into a patient, the tracer circulates through the bloodstream and accumulates in areas where uPAR is present, particularly in tumor tissue. The radioactive gallium-68 emits signals that are detected by the PET scanner, creating images that show where the tracer has accumulated.

Primary Trial Objectives

The Phase 1 trial has several specific objectives designed to evaluate the clinical utility of [68Ga]GA-NOTA-AE105 imaging in glioma patients^[1].

Correlation with Tissue Analysis

A fundamental objective is establishing whether tracer uptake on imaging correlates with actual uPAR expression in tumor tissue^[1]. Researchers collect tumor samples through stereotactic biopsies or during surgical procedures and analyze them using immunohistochemical techniques to measure uPAR protein levels^[1]. These tissue analysis results are then compared with the tracer uptake patterns seen on PET images to determine if the imaging accurately reflects the biological characteristics of the tumor.

Preoperative Assessment

The trial evaluates whether [68Ga]GA-NOTA-AE105 imaging can provide valuable information before surgery or other treatments^[1]. Specifically, researchers are testing whether the imaging can help doctors distinguish between tumor progression or recurrence and post-therapeutic effects before making treatment decisions^[1]. This preoperative differentiation capability could help avoid unnecessary surgeries in cases where imaging changes are due to treatment effects rather than actual tumor growth.

Prognostic Value Assessment

An important trial objective is determining whether the level of [68Ga]GA-NOTA-AE105 uptake in brain tumors can predict patient survival^[1]. The study examines whether patients with high tracer uptake in their tumors have shorter survival times compared to those with lower uptake^[1]. This prognostic information could help guide treatment intensity and provide patients and families with more accurate expectations about disease course.

Patient Population and Enrollment

The Phase 1 clinical trial investigating [68Ga]GA-NOTA-AE105 has enrolled 61 patients with gliomas^[1]. This enrollment number is typical for early-phase imaging studies, providing enough participants to evaluate the tracer’s performance across different tumor types and grades.

Study Design

The trial is classified as an interventional study, meaning that participants receive the imaging tracer as part of the research protocol^[1]. The study has received authorization to proceed, indicating that regulatory authorities have reviewed and approved the research plan^[1]. As a Phase 1 trial, the study focuses on establishing basic safety and feasibility while also gathering preliminary data on the tracer’s ability to image gliomas effectively.

Patient Selection

While specific inclusion and exclusion criteria are not detailed in the available trial information, patients enrolled in this study typically have confirmed or suspected gliomas requiring imaging for diagnosis, treatment planning, or monitoring^[1]. The study likely includes patients with various glioma grades and types to evaluate how well the tracer performs across the spectrum of these brain tumors.

Potential Clinical Applications

The research investigating [68Ga]GA-NOTA-AE105 could lead to several important clinical applications if the trial objectives are successfully met^[1].

Improved Diagnosis

If the tracer effectively visualizes gliomas and correlates with uPAR expression, it could become a valuable diagnostic tool^[1]. Doctors could use [68Ga]GA-NOTA-AE105 imaging to better identify tumor boundaries, which is crucial for surgical planning. More accurate visualization of tumor extent could help surgeons remove more tumor tissue while preserving healthy brain tissue.

Tumor Grading

The ability to differentiate between high-grade and low-grade gliomas based on tracer uptake could reduce the need for invasive biopsies in some cases^[1]. This non-invasive grading capability would be particularly valuable for tumors located in areas of the brain where biopsy carries significant risks. Knowing the tumor grade helps doctors recommend appropriate treatment strategies, as high-grade and low-grade gliomas require different therapeutic approaches.

Treatment Monitoring

One of the most challenging aspects of managing glioma patients is determining whether changes on imaging scans represent tumor recurrence or treatment effects^[1]. If [68Ga]GA-NOTA-AE105 imaging can reliably make this distinction, it could prevent unnecessary surgeries or treatments in patients whose imaging changes are due to treatment effects rather than tumor growth. Conversely, it could help identify true recurrence earlier, allowing for timely intervention.

Prognostic Information

If high tracer uptake correlates with shorter survival, [68Ga]GA-NOTA-AE105 imaging could provide valuable prognostic information^[1]. This information could help doctors and patients make more informed decisions about treatment intensity and help with care planning. Prognostic imaging biomarkers could also be useful in clinical trial design, helping to stratify patients by risk level.

Treatment Planning

Detailed imaging of uPAR expression in gliomas could potentially guide targeted therapies in the future^[1]. If certain areas of a tumor show particularly high uPAR expression, these regions might be targeted more aggressively with radiation therapy or other treatments. The imaging could also help identify patients who might benefit from therapies targeting the uPAR pathway.

Table of Contents

• Overview of Clinical Research
• Understanding the Imaging Agent
• Trial Design and Objectives
• Target Patient Population
• Study Methodology and Administration
• Primary Outcomes and Measurements
• Clinical Significance

Overview of Clinical Research

Clinical trials are currently investigating [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2, also known as [68Ga]NODAGA-E[c(RGDyK)]2, as a specialized imaging agent for patients with heart disease^[1]. This research represents an important advancement in cardiac imaging technology, focusing on the ability to visualize and measure new blood vessel formation in the heart muscle.

The primary research initiative is an authorized Phase 2 interventional study that aims to evaluate how effectively this radioactive tracer can detect angiogenesis in patients with chronic ischemic heart disease^[1]. Angiogenesis refers to the body’s natural process of creating new blood vessels, which is particularly important in heart disease where blood flow to the heart muscle is compromised.

The trial is designed to assess changes in angiogenesis patterns at two critical time points: before patients undergo coronary revascularization procedures and after these procedures are completed^[1]. This comparative approach allows researchers to understand how the heart’s blood vessel network responds to treatment interventions.

Understanding the Imaging Agent

[68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is a radioactive compound used specifically for PET imaging (Positron Emission Tomography)^[1]. The substance contains gallium-68, a radioactive isotope that emits signals detectable by PET scanners, allowing doctors to create detailed images of internal body structures and processes.

The compound is also referred to by its shortened name, [68Ga]NODAGA-E[c(RGDyK)]2, in clinical documentation^[1]. The “RGD” portion of the name refers to a specific sequence of amino acids (arginine-glycine-aspartic acid) that has the ability to bind to proteins involved in new blood vessel formation. This binding property makes the substance particularly useful for imaging angiogenesis.

When injected into patients, the substance travels through the bloodstream and accumulates in areas where new blood vessels are forming^[1]. The radioactive component allows these areas to be visualized on PET scans as regions of increased uptake, providing doctors with a map of where angiogenesis is occurring in the heart muscle.

Trial Design and Objectives

The clinical trial investigating [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is structured as a Phase 2 interventional study with authorization status^[1]. Phase 2 trials are designed to evaluate how well a diagnostic tool or treatment works in a larger group of patients while continuing to monitor safety.

The study has a planned enrollment of 42 participants, which provides a sufficient sample size to evaluate the imaging capabilities of the substance in the target population^[1]. This enrollment number is typical for Phase 2 imaging studies, balancing the need for meaningful data with practical considerations of patient recruitment and study resources.

The trial’s primary objective is clearly defined: to characterize the difference in myocardial angiogenesis measured with RGD-PET uptake before and after coronary revascularization^[1]. This objective addresses a critical question in cardiac care: how does the heart’s ability to form new blood vessels change after procedures designed to restore blood flow.

The study design follows a longitudinal approach, meaning patients undergo imaging at multiple time points throughout their treatment journey^[1]. This allows researchers to track changes in angiogenesis within the same patients, providing more reliable data than comparing different groups of patients.

Target Patient Population

The clinical trial specifically targets patients diagnosed with chronic ischemic heart disease^[1]. This condition occurs when the coronary arteries, which supply blood to the heart muscle, become narrowed or blocked over time, typically due to the buildup of fatty deposits called plaques.

Patients with chronic ischemic heart disease often experience symptoms such as chest pain (angina), shortness of breath, and reduced exercise tolerance^[1]. The chronic nature of the condition means these patients have had reduced blood flow to their heart muscle for an extended period, which can trigger the body’s natural angiogenesis response as it attempts to create new pathways for blood flow.

The study specifically enrolls patients who are scheduled to undergo coronary revascularization procedures^[1]. These procedures include interventions such as:

• Percutaneous coronary intervention (PCI): A procedure where blocked arteries are opened using a balloon and often a stent (a small mesh tube) to keep the artery open
• Coronary artery bypass grafting (CABG): Surgery where healthy blood vessels from other parts of the body are used to create new pathways around blocked coronary arteries

By focusing on patients undergoing these procedures, the trial can evaluate how revascularization affects the heart’s natural angiogenesis processes and whether the imaging agent can effectively capture these changes^[1].

Study Methodology and Administration

In the clinical trial, [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is administered to participants through injection^[1]. The standardized dose used in the study is 300 megabecquerels (MBq), which represents the amount of radioactivity in the injected substance.

The administration process follows a specific protocol^[1]:

1. Pre-imaging preparation: Patients are prepared for the PET scan according to standard imaging protocols
2. Injection: The 300 MBq dose of [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 is administered intravenously
3. Distribution period: After injection, time is allowed for the substance to circulate through the bloodstream and accumulate in areas of angiogenesis
4. PET imaging: Patients undergo PET scanning to capture images of the radioactive tracer uptake in the heart muscle

The imaging technique used is referred to as RGD-PET, which specifically refers to PET imaging using substances containing the RGD peptide sequence^[1]. This specialized imaging approach allows for targeted visualization of angiogenesis markers in the heart tissue.

Patients undergo this imaging procedure at two distinct time points: once before their scheduled coronary revascularization procedure and again afterward^[1]. This before-and-after approach enables researchers to directly compare angiogenesis patterns and measure any changes resulting from the revascularization treatment.

Primary Outcomes and Measurements

The primary outcome measure of the trial focuses on characterizing the difference in myocardial angiogenesis as measured by RGD-PET uptake before and after coronary revascularization^[1]. This outcome is quantitative, meaning researchers will use numerical measurements to assess changes in angiogenesis.

The measurement of uptake refers to how much of the radioactive tracer accumulates in the heart muscle tissue^[1]. Areas with active angiogenesis show higher uptake of the substance because the RGD component binds to proteins expressed during new blood vessel formation. These areas appear as brighter regions on PET images.

Researchers will analyze several aspects of the imaging data:

• Baseline angiogenesis: The pattern and intensity of tracer uptake before revascularization, showing where the heart is attempting to form new blood vessels in response to chronic ischemia
• Post-revascularization changes: How the angiogenesis pattern changes after blood flow is restored through revascularization procedures
• Regional differences: Whether certain areas of the heart muscle show more pronounced changes in angiogenesis than others
• Quantitative measurements: Specific numerical values representing the amount of tracer uptake in different regions of the heart

By characterizing these differences, the trial aims to provide detailed information about how the heart’s natural healing processes respond to medical interventions^[1]. This information could potentially help doctors better understand treatment effectiveness and predict patient outcomes.

Clinical Significance

The investigation of [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 for imaging angiogenesis in chronic ischemic heart disease represents an important area of cardiovascular research^[1]. Understanding how new blood vessels form in response to ischemia and treatment could have several clinical implications.

Currently, doctors assess the success of coronary revascularization procedures primarily by evaluating blood flow restoration and symptom improvement^[1]. However, the ability to visualize and measure angiogenesis could provide additional information about the heart’s biological response to treatment. This could help identify patients who are healing well versus those who may need additional interventions.

The trial’s focus on characterizing angiogenesis patterns before and after revascularization could help answer important clinical questions^[1]:

• Does successful revascularization enhance the heart’s natural angiogenesis processes?
• Are there patients in whom angiogenesis continues despite restored blood flow?
• Can imaging predict which patients will have better long-term outcomes?
• Does the degree of angiogenesis correlate with symptom improvement?

For patients with chronic ischemic heart disease, the development of effective imaging techniques for angiogenesis could lead to more personalized treatment approaches^[1]. If doctors can visualize how individual patients’ hearts are forming new blood vessels, they may be able to tailor treatments more effectively.

The use of PET imaging with [68Ga]NODAGA-GLU(CYCLO[-ARG-GLY-ASP-D-TYR-LYS)]2 offers advantages over other imaging methods because it provides functional information about biological processes rather than just anatomical pictures^[1]. This functional imaging capability could complement existing diagnostic tools and provide a more complete picture of heart health.

As the trial progresses through Phase 2, the data collected will help determine whether this imaging approach should advance to larger Phase 3 studies^[1]. Successful completion of this research could eventually lead to the availability of RGD-PET imaging as a clinical tool for managing patients with chronic ischemic heart disease, potentially improving treatment planning and outcome prediction.

Table of Contents

• What is [AL[18F]F]FAPI-74?
• How does [AL[18F]F]FAPI-74 work?
• What conditions is [AL[18F]F]FAPI-74 being studied for?
• How is [AL[18F]F]FAPI-74 administered?
• Potential benefits of [AL[18F]F]FAPI-74
• Ongoing research and clinical trials
• Safety considerations

What is [AL[18F]F]FAPI-74?

[AL[18F]F]FAPI-74 is an innovative diagnostic tool being studied for its potential in detecting various types of cancers^[1]. It is a radioactive tracer used in a special type of imaging called PET/CT (Positron Emission Tomography/Computed Tomography). This substance is also known by other names such as [18F]-AlF-FAPI-74 or simply 18F-FAPI-74^[2].

How does [AL[18F]F]FAPI-74 work?

[AL[18F]F]FAPI-74 works by targeting a specific protein called Fibroblast Activation Protein (FAP). This protein is often found in high amounts in the tissue surrounding various types of tumors. When [AL[18F]F]FAPI-74 is injected into the body, it attaches to these FAP proteins, allowing doctors to see where cancer might be present using a PET/CT scanner^[3].

What conditions is [AL[18F]F]FAPI-74 being studied for?

Research is ongoing to evaluate the effectiveness of [AL[18F]F]FAPI-74 in diagnosing and monitoring several types of cancers, including:

• Progressive Pulmonary Fibrosis (PPF): A condition where the lungs become scarred over time^[1].
• Carcinoma of Unknown Primary (CUP): A type of cancer where doctors can’t determine where the cancer originally started^[2].
• Pancreatic cancer: Cancer that starts in the pancreas^[4].
• Colon cancer: Cancer that begins in the large intestine (colon)^[5].
• Prostate cancer: Cancer that occurs in the prostate gland^[6].
• Biliary tract cancers: Cancers that occur in the bile ducts^[3].

How is [AL[18F]F]FAPI-74 administered?

[AL[18F]F]FAPI-74 is given as a solution for injection. It is typically administered through an intravenous (IV) injection, which means it’s injected directly into a vein^[1][2]. The dose can vary, but studies have used amounts ranging from 250 to 400 MBq (megabecquerels, a unit of radioactivity)^[4][6].

Potential benefits of [AL[18F]F]FAPI-74

The potential benefits of [AL[18F]F]FAPI-74 include:

• Improved detection of cancer spread: It may help doctors identify if cancer has spread to lymph nodes or other parts of the body more accurately than current methods^[4][5].
• Identifying unknown primary tumors: In cases where the origin of cancer is unknown, [AL[18F]F]FAPI-74 might help locate the primary tumor^[2].
• Distinguishing between inflammation and active fibrosis: This could be particularly useful in conditions like pulmonary fibrosis^[1].
• Guiding treatment decisions: By providing more accurate information about a patient’s cancer, it could help doctors make better decisions about treatment^[3].

Ongoing research and clinical trials

Several clinical trials are currently underway to evaluate the effectiveness of [AL[18F]F]FAPI-74 in various cancers. These studies aim to determine:

• The accuracy of [AL[18F]F]FAPI-74 in detecting cancer spread^[4][5].
• How well it performs compared to other imaging techniques^[6].
• Its ability to guide treatment decisions and improve patient outcomes^[3].
• The optimal dose and timing for [AL[18F]F]FAPI-74 PET/CT scans^[1][2].

Safety considerations

While [AL[18F]F]FAPI-74 appears promising, it’s important to note that it’s still being studied and is not yet approved for widespread clinical use. As with any medical procedure involving radiation, there are some safety considerations:

• The procedure exposes patients to a small amount of radiation^[1].
• It’s not recommended for pregnant or breastfeeding women^[3].
• Patients with severely impaired kidney function may need special consideration^[3].
• As with any injection, there’s a small risk of allergic reaction^[3].

Always consult with your healthcare provider to understand the potential risks and benefits of participating in a clinical trial or undergoing any new diagnostic procedure.

Table of Contents

• What is ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM?
• How does it work?
• What is it used for?
• How is it administered?
• Potential side effects
• Ongoing research

What is ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is an innovative imaging agent used in positron emission tomography (PET) scans. It is also known by several other names, including:

• Zirconium Zr 89 crefmirlimab berdoxam
• 89Zr-Df-IAB22M2C
• 89Zr-desferrioxamine-IAB22M2C
• RO7499775

This compound is not a drug used to treat diseases, but rather a diagnostic tool to help doctors visualize certain cells in the body^[1].

How does it work?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM works by targeting and attaching to CD8+ T cells in the body. CD8+ T cells are a type of immune cell that plays a crucial role in fighting cancer and infections. The zirconium-89 component of the compound emits a small amount of radiation that can be detected by a PET scanner, allowing doctors to see where these important immune cells are located in the body^[2].

What is it used for?

This imaging agent is being studied for use in several medical conditions:

1. Cancer: It can help doctors visualize how the immune system is responding to cancer, particularly in patients receiving immunotherapy treatments. This includes:
   • Non-small cell lung cancer
   • Metastatic melanoma (skin cancer that has spread)
   • Other solid tumors
2. Inflammatory diseases:
   • Rheumatoid arthritis (a condition causing joint inflammation)
   • Giant cell arteritis (inflammation of blood vessels, typically in the head)

By showing where CD8+ T cells are concentrated, this imaging technique can help doctors:

• Assess how well cancer treatments are working
• Predict which patients might respond best to certain therapies
• Detect early signs of side effects from immunotherapy
• Monitor inflammation in autoimmune diseases

^[3][4][5]

How is it administered?

ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is given as an intravenous injection or infusion. This means it is delivered directly into a vein. The dose is typically measured in megabecquerels (MBq), which is a unit used to measure radioactivity. After receiving the injection, patients undergo a PET/CT scan, usually within a few hours to a few days^[1][5].

Potential side effects

As ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM is a diagnostic agent used in very small quantities, severe side effects are rare. However, potential risks may include:

• Allergic reactions to the compound
• Mild discomfort at the injection site
• Exposure to a small amount of radiation (less than many standard medical imaging procedures)

Patients should inform their healthcare providers of any unusual symptoms or concerns after receiving this imaging agent^[5].

Ongoing research

Several clinical trials are currently underway to further investigate the uses of ZIRCONIUM (89ZR) CREFMIRLIMAB BERDOXAM:

• A study comparing it to another imaging agent in non-small cell lung cancer patients receiving immunotherapy^[1]
• Research on its ability to detect early signs of side effects in melanoma patients receiving immune checkpoint inhibitor therapy^[4]
• Investigations into its use for imaging inflammation in rheumatoid arthritis and giant cell arteritis^[3]
• A study examining its effectiveness in predicting treatment response in various solid tumors^[5]

These studies aim to improve our understanding of how this imaging technique can be used to enhance patient care and treatment decisions.

Table of Contents

• Trial overview
• Who is being studied
• What the trials measure
• Trial phases and status
• Trial details

Trial overview

ZIRCONIUM (89ZR) GIRENTUXIMAB is being studied in two authorised interventional trials.^[1][2] Both trials focus on imaging, meaning they are designed to see how well scans can find tumors in specific patient groups.^[1][2]

Who is being studied

One trial includes patients with suspected primary, recurrent, or metastatic clear cell renal cell carcinoma (ccRCC), which is a type of kidney cancer.^[1] The other trial includes people with Von-Hippel Lindau (VHL) disease, a rare inherited condition linked to tumor growth.^[2]

The first study is listed for metastatic renal cell carcinoma, meaning kidney cancer that has spread to other parts of the body.^[1] The second study explores the role of Carbonic Anhydrase IX, also called CAIX, as a diagnostic and theranostic target in VHL disease.^[2]

What the trials measure

The Phase 3 study compares the tumor detection rate of 68Ga-gozetotide PET-CT with ZIRCONIUM (89ZR) GIRENTUXIMAB PET-CT, both added to conventional contrast enhanced CT.^[1] Its main outcome is tumor detectability, which means how well each scan can find tumors.^[1]

The Phase 2 study measures the efficacy of CAIX-PET for detecting tumors in patients with VHL disease.^[2] In simple terms, it asks whether the scan works well for finding tumors in this group.^[2]

Trial phases and status

One study is Phase 3 and has an enrollment of 20 participants.^[1] The other is Phase 2 and has an enrollment of 38 participants.^[2]

Both studies are currently listed as Authorised.^[1][2] They are both interventional studies, meaning researchers actively apply the imaging procedure and then measure the results.^[1][2]

Trial details

The study titled ISEE-RCC study compares ZIRCONIUM (89ZR) GIRENTUXIMAB PET-CT with 68Ga-gozetotide PET-CT and conventional contrast enhanced CT in patients with suspected metastatic ccRCC.^[1] Its brief summary says the study is exploratory and looks at tumor detection visually and semi-quantitatively, which means the scans are reviewed by eye and also by numbers.^[1]

The study titled CAT-VHL – Exploring the role of Carbonic Anhydrase IX as diagnostic and Theranostic target in Von-Hippel Lindau disease evaluates CAIX-PET for detecting tumors in VHL disease.^[2] Its brief summary says it is exploring Carbonic Anhydrase IX as a diagnostic and theranostic target, meaning a target that may help both with finding disease and guiding future care.^[2]

Table of contents

• Trial overview
• Who is being studied
• What is being measured
• Study design and phase
• Why this research matters

Trial overview

This source describes one interventional study, which means the researchers give a study treatment and then measure what happens.^[1] The trial title is “Mechanisms of Action of Paradoxical Responses to Zolpidem: A Multimodal Study.”^[1] The study status is Suspended, so it is not currently moving ahead as planned.^[1]

Who is being studied

The trial includes three groups: patients with disorders of consciousness (DoC), patients with acquired partial or total vision impairment, and neurotypical volunteers, which means people from the general population used for comparison.^[1] The brief summary says the researchers are interested in people who may show a paradoxical response to ZOLPIDEM TARTRATE, meaning an unexpected response rather than the usual one.^[1]

In the DoC group, the researchers are looking at whether some participants may recover consciousness after the study intervention.^[1] In the vision-impaired group, they are looking at whether some participants may have a temporary return of vision.^[1] In neurotypical volunteers, the summary notes possible changes such as trouble falling asleep, higher concentration, and increased agitation in paradoxical responders.^[1]

What is being measured

The main outcomes are different for each group, but they all help researchers understand response patterns.^[1] For patients with DoC, the study measures consciousness level using the Coma Recovery Scale-Revised (CRS-R), brain complexity using high density electroencephalography (hdEEG), and patient experiences through free recall or interview if functional communication returns.^[1]

For neurotypical volunteers, the study measures alertness or sleepiness with the Karolinska Sleepiness Scale (KSS), cognitive performance with standardised neuropsychological tests, brain complexity with hdEEG, and any reported experiences through free recall or interview.^[1] For patients with acquired vision impairment, the same alertness, cognitive, brain, and experience measures are used, plus visual function testing by a neuro-ophthalmologist, who is an eye specialist focused on the nervous system and vision.^[1]

Study design and phase

The study is listed as Phase 2.^[1] Phase 2 studies usually look more closely at whether a treatment has an effect in the target groups and continue to collect information about outcomes.^[1] The planned enrollment is 180 participants.^[1]

The intervention list includes Zolpidem Viatris 10 mg tablets and mannitol, with administration by oral, nasogastric tube, or percutaneous endoscopic gastrostomy tube use as stated in the source.^[1] The source does not provide more detail on dosing schedules beyond this listing.^[1]

Why this research matters

The brief summary says the study aims to better understand the mechanisms behind paradoxical responders versus non-paradoxical responders to ZOLPIDEM TARTRATE.^[1] This matters because the same treatment may lead to very different results across people, and the researchers want to learn which brain, behavior, or vision changes may help explain those differences.^[1] The summary also says the findings could support improved personalised patient care.^[1]

Table of Contents

• Trial overview
• Who was studied
• How the trials were designed
• Main endpoints
• What the trials aimed to show
• Completed studies

Trial overview

Clinical trials are studying Xevinapant in people with squamous cell carcinoma of the head and neck, which is a cancer that starts in the lining cells of the mouth, throat, voice box, or nearby areas.^[1][2][3]

These studies look at Xevinapant given with radiotherapy, and in one trial with cetuximab plus radiotherapy, to see whether outcomes are better than with placebo.^[1][2][3]

Who was studied

The trials included different patient groups with head and neck cancer.^[1][2][3]

• Resected disease: one study enrolled people whose cancer had been removed by surgery and who were at high risk.^[1]

• Locally advanced disease: two studies focused on cancer that had grown beyond an early stage, but was still being treated in the head and neck area.^[2][3]

• Older patients: one Phase 2 study specifically studied older people with locally advanced head and neck cancer.^[2]

• Cisplatin-ineligible participants: one Phase 3 study included people who could not receive cisplatin, a common cancer treatment, based on the trial title.^[1]

How the trials were designed

All three studies were interventional, which means the researchers assigned study treatments to compare outcomes.^[1][2][3]

Two trials were Phase 3 studies, and one was a Phase 2 study.^[1][2][3]

Phase 2 studies usually look for early signs that a treatment may help, while Phase 3 studies compare treatments in larger groups of people.^[2][1][3]

• One Phase 3 study compared Xevinapant plus radiotherapy with placebo plus radiotherapy after surgery in high-risk people who could not receive cisplatin.^[1]

• One Phase 2 study compared Xevinapant plus radiotherapy with placebo plus radiotherapy in older patients.^[2]

• One Phase 3 study compared Xevinapant plus cetuximab plus radiotherapy with placebo plus cetuximab plus radiotherapy.^[3]

Main endpoints

The trials were built around survival and cancer-control outcomes.^[1][2][3]

• Disease-free survival (DFS) was the main outcome in the Phase 3 post-surgery study.^[1]

• Locoregional event-free survival (LREFS) was the main outcome in the Phase 2 older-patient study. This means the study tracked how long people stayed free from cancer return or worsening in the same area or nearby area, new head and neck cancer in the radiation field, or death from any cause.^[2]

• Progression-free survival (PFS) was the main outcome in the Phase 3 cetuximab study. This measures the time until the cancer gets worse, treatment fails before a complete response, or the cancer comes back after a complete response, or death occurs.^[3]

What the trials aimed to show

The main purpose of the Phase 3 post-surgery study was to show better disease-free survival when Xevinapant was added to radiotherapy, compared with placebo plus radiotherapy, regardless of later cancer treatment.^[1]

The Phase 2 study aimed to find out whether adding Xevinapant to radiotherapy could improve locoregional event-free survival in older patients with locally advanced head and neck cancer.^[2]

The Phase 3 cetuximab study aimed to show better progression-free survival with Xevinapant-cetuximab-radiotherapy compared with placebo-cetuximab-radiotherapy.^[3]

Completed studies

All three trials in the source data are listed as completed, which means the planned study work has ended.^[1][2][3]

The completed studies include a large Phase 3 trial with 648 participants, a Phase 2 trial with 244 participants, and another Phase 3 trial with 377 participants.^[1][2][3]

Table of Contents

• Trial overview
• COPD study and physical capacity
• Intranasal analgesia study during nasotracheal intubation
• Study design and participants
• Endpoints and outcome measures
• Trial status and enrollment

Trial overview

These records describe interventional clinical trials, which means researchers gave a treatment or procedure and then measured the results.^[1][2] The trials investigate XYLOMETAZOLINE HYDROCHLORIDE in two different clinical settings: COPD and nasotracheal intubation.^[1][2] Both studies are in Phase 3, which is a later stage of testing in people.^[1][2]

COPD study and physical capacity

One trial, NCT 2024-520177-12-00, is an authorised Phase 3 study in people with Chronic Obstructive Pulmonary Disease (COPD).^[1] Its goal is to assess the effect of one dose on the physical capacity of patients with COPD.^[1] The main result being measured is walking distance, which helps show how far a person can walk as a sign of physical ability.^[1]

Intranasal analgesia study during nasotracheal intubation

The second trial, NCT 2023-506644-17-01, is a completed Phase 3 blinded triple crossover study in patients undergoing nasotracheal intubation.^[2] A blinded triple crossover study means the treatment order is compared across several approaches, and the people involved do not know which treatment is being given at a given time.^[2] This study compares cocaine, lidocaine/xylometazoline, and saline for intranasal analgesia, which means pain relief given through the nose.^[2]

Study design and participants

The COPD study includes patients with a long-term lung disease that can make breathing difficult.^[1] The intubation study includes patients who need a breathing tube placed through the nose.^[2] Together, these trials show that XYLOMETAZOLINE HYDROCHLORIDE is being studied in very different groups of patients rather than in one single disease area.^[1][2]

Endpoints and outcome measures

A primary outcome is the main result a study is designed to measure.^[1][2] In the COPD study, the primary outcome is walking distance.^[1] In the intubation study, the primary outcome is self-reported pain during the procedure, measured with a visual analogue scale from 0 to 100.^[2] This scale is a simple way for patients to rate pain, with higher numbers showing more pain.^[2]

Trial status and enrollment

The COPD study is listed as Authorised and plans to include 64 participants.^[1] The intranasal analgesia study is listed as Completed and included 12 participants.^[2] Enrollment means the number of people planned or included in a study.^[1][2]

Table of Contents

• What is XENON (129XE)?
• Medical Conditions XENON (129XE) is Used For
• How XENON (129XE) Works
• How XENON (129XE) is Administered
• Who Can Use XENON (129XE)?
• Safety Considerations
• Research Goals and Potential Benefits

What is XENON (129XE)?

XENON (129XE) is a special form of xenon gas used as an imaging agent in medical research^[1]. It’s not a traditional medication that treats diseases directly, but rather a tool doctors use to get better pictures of what’s happening inside your lungs. The technical name for this type of imaging agent is a contrast agent, which helps make certain parts of your body show up more clearly on medical scans.

Medical Conditions XENON (129XE) is Used For

XENON (129XE) is being studied for use in patients with a group of lung diseases called Progressive Fibrosing Interstitial Lung Diseases (ILDs)^[2]. These are conditions where the lungs become scarred over time, making it harder to breathe. Some examples include:

• Idiopathic Pulmonary Fibrosis (IPF): A type of lung disease where the cause of the scarring is unknown
• Other types of fibrotic ILDs that get worse over time

The goal is to use XENON (129XE) to help doctors better understand and monitor these diseases.

How XENON (129XE) Works

XENON (129XE) is used in a special type of imaging called Magnetic Resonance Imaging (MRI)^[3]. Here’s how it works:

1. The xenon gas is made into a special form called “hyperpolarized,” which makes it show up very clearly on MRI scans.
2. When you breathe in the gas, it travels into your lungs and even dissolves slightly into your blood and tissues.
3. The MRI machine can then create detailed images of your lungs, showing how well air is flowing and how the gas is moving into your blood.

This gives doctors a unique view of how your lungs are functioning, which isn’t possible with regular MRI or CT scans.

How XENON (129XE) is Administered

XENON (129XE) is given as an inhalation solution, which means you breathe it in^[4]. The amount you inhale can vary, but typically ranges from 400 ml to 1000 ml (about 1/2 to 1 liter). You’ll be asked to hold your breath for a short time (at least 20 seconds) while the images are taken.

Who Can Use XENON (129XE)?

XENON (129XE) is currently being studied in specific groups of people. You might be eligible if you:

• Have been diagnosed with a progressive fibrosing interstitial lung disease
• Are prescribed anti-fibrotic treatment (medications to slow down lung scarring)
• Can understand and participate in the study
• If you’re a woman of childbearing age, you must not be pregnant

Safety Considerations

While XENON (129XE) is generally considered safe, there are some people who shouldn’t use it^[5]:

• People with certain metal implants or devices (like pacemakers) that aren’t safe for MRI
• Those who are claustrophobic (fear of enclosed spaces)
• People who can’t hold their breath for at least 20 seconds
• Anyone allergic to xenon
• Those with ongoing respiratory infections

It’s important to discuss any health conditions or concerns with your doctor before participating in a study using XENON (129XE).

Research Goals and Potential Benefits

The main goals of research using XENON (129XE) include^[6]:

1. Finding early signs of pulmonary fibrosis (lung scarring)
2. Monitoring how lung diseases progress over time
3. Evaluating how well anti-fibrotic treatments are working
4. Assessing how lung disease might be affecting heart function

By providing more detailed information about lung function, XENON (129XE) imaging could potentially help doctors:

• Diagnose lung diseases earlier
• Make more informed decisions about treatment
• Better understand how treatments are working

This research is still ongoing, and XENON (129XE) is not yet widely available outside of clinical trials. However, it represents an exciting new tool in the field of lung disease research and treatment.

Table of contents

• Trial overview
• Who is being studied
• What the trial is measuring
• Phase and status
• Why this research matters for patients

Trial overview

This clinical trial is titled Pre- and post-treatment evaluation of lung function with Xenon-gas enhanced Dual-Energy CT-imaging in patients undergoing radiotherapy^[1].

It is an interventional study, which means researchers actively give the study intervention and then measure what happens^[1].

The trial is testing imaging with a gas mixture of 30 Vol% Xe in 70 Vol% O2 as a contrast agent, used together with Dual-Energy CT imaging to study the lungs^[1].

Who is being studied

The trial includes patients with lung cancer and breast cancer who are scheduled to undergo radiotherapy^[1].

The study also targets people at risk of radiation-induced lung injury, including radiation pneumonitis and radiation fibrosis^[1].

Enrollment is planned for 40 participants, so this is a relatively small study focused on detailed imaging results^[1].

What the trial is measuring

The main endpoint is to quantify radiotherapy-related changes in lung function by comparing pre-treatment and post-treatment ventilation maps^[1].

Researchers will assess these changes in two ways: first by visual review of lung tissue and ventilation patterns, and second by numerical comparison of local ventilation metrics^[1].

The study looks for areas that appear hypo- or hyperdense on colour-coded Xe-concentration maps, because these patterns may show how the lungs respond to treatment^[1].

Phase and status

This trial is listed as Phase 4^[1].

The status is Authorised, which means the study has been approved to proceed^[1].

Phase 4 studies are often used to learn more about how a method performs in a more real-world setting after earlier development stages, although this trial is specifically focused on imaging results rather than treatment effect^[1].

Why this research matters for patients

This research may help doctors and researchers better understand how radiotherapy affects the lungs in people treated for lung cancer or breast cancer^[1].

By comparing lung images before and after treatment, the study may show where lung function changes happen and how strong those changes are^[1].

That information can support future work on monitoring lung injury after radiotherapy, especially for problems such as pneumonitis and fibrosis^[1].

Table of Contents

• Clinical trial overview
• Patient groups being studied
• Trial phases and study designs
• Main endpoints and outcomes
• Imaging tests and follow-up periods
• What participation means in these studies
• Key trials using Warfarin Sodium

Clinical trial overview

The trials in this set study Warfarin Sodium in people with different conditions linked to blood clots and bleeding risk.^[1][2] Most studies are designed to compare Warfarin Sodium with other anticoagulants, with no treatment, or with another antithrombotic strategy.^[1][3]

These are mostly Phase 3 trials, which means they are testing treatments in larger groups and comparing results across groups.^[1][6] One study is in Phase 4, which usually looks at treatment effects after wider use has already started.^[5]

Patient groups being studied

Several trials focus on people with atrial fibrillation, a heart rhythm problem that can increase the risk of stroke and blood clots.^[2][5][8] Other studies include patients on dialysis, people after heart surgery, and patients with clots inside the heart or left ventricle.^[1][3][7]

Some studies also include people after transcatheter aortic valve implantation, often called TAVI, which is a procedure to place a new aortic valve without open-heart surgery.^[6] One trial looks at people with acute venous thromboembolism who are also taking antiplatelet therapy for artery protection.^[9]

Trial phases and study designs

All of the listed studies are interventional, meaning researchers assign the treatment plan and then compare outcomes.^[1][4] The trials include randomized controlled designs, open-label designs, and pragmatic multicenter studies, which means they are built to reflect real-world care in more than one hospital or center.^[1][4]

Enrollment ranges from small exploratory work to very large studies, from 100 participants up to 2,600 participants in the listed trials.^[4][6] This wide range shows that some studies are focused on detailed safety checks, while others aim to compare treatment strategies in broader patient groups.^[2][9]

Main endpoints and outcomes

The main outcomes often measure bleeding events, stroke, embolism, death, or whether a clot gets smaller or disappears.^[1][3][7] Some trials use a composite endpoint, which means several important outcomes are grouped together in one main result.^[2][5]

For example, one study measures clinically significant major or non-major bleeding, while another looks at stroke, peripheral embolism, and major bleeding events together.^[1][2] Another trial focuses on net clinical benefit, which combines death, heart attack, stroke, embolism, clot persistence, and relevant bleeding in a single outcome.^[3]

Some studies use specific bleeding scales, such as ISTH, GUSTO, TIMI, BARC, or VARC-3, to classify how serious a bleeding event is.^[1][5][6][9] These scales help researchers compare results in a standard way.

Imaging tests and follow-up periods

Several trials use imaging tests to see whether a clot has resolved or whether a valve looks changed over time.^[7][6] For example, one study checks thrombus resolution with transthoracic echocardiography, and if that is unclear, it may use cardiac MRI or cardiac CT.^[7]

Follow-up times vary by study. Some outcomes are measured at 3 months, 6 months, 12 months, or even 2 years, depending on the condition and the goal of the trial.^[3][5][7][8]

What participation means in these studies

People in these trials are usually already living with a condition that raises clotting or bleeding concerns, such as atrial fibrillation, dialysis, recent heart procedures, or a known clot.^[1][6][8] The studies compare different treatment approaches so researchers can see which strategy gives the best balance between preventing clots and avoiding bleeding.^[2][9]

Some trials compare Warfarin Sodium with newer oral anticoagulants such as apixaban, rivaroxaban, dabigatran, or edoxaban.^[1][2][7] Other studies compare Warfarin Sodium with no anticoagulant treatment or with different antithrombotic plans after a procedure.^[2][5]

Key trials using Warfarin Sodium

NCT06045858 is a Phase 3 randomized study in people with end-stage renal disease on chronic peritoneal dialysis and non-valvular atrial fibrillation.^[1] It compares apixaban with warfarin and measures clinically significant bleeding over 12 months.^[1]

2022-502986-92-00 is a large Phase 3 study in atrial fibrillation after surgical left atrial appendage closure.^[2] It looks at whether anticoagulant therapy, including Warfarin Sodium, changes the risk of stroke, peripheral embolism, and major bleeding.^[2]

2024-512685-33-00 studies people with intra-cardiac thrombus and compares direct oral anticoagulants with vitamin K antagonist therapy, including warfarin.^[3] Its main result is a 6-month net clinical benefit endpoint that includes death, heart attack, stroke, embolism, clot persistence, and bleeding.^[3]

NCT06696079 is a Phase 4 study in chronic subdural hematoma with atrial fibrillation.^[5] It asks whether restarting anticoagulation early or later changes the risk of thromboembolic events, hemorrhagic events, and vascular death.^[5]

NCT06449469 studies patients after successful TAVI and measures whether at least one prosthetic valve leaflet shows HALT, which means hypoattenuated leaflet thickening on cardiac CT.^[6] This trial looks at how different antithrombotic strategies affect this valve finding over one year.^[6]

NCT06515730 compares apixaban and Warfarin Sodium in people with left ventricular thrombus after acute myocardial infarction.^[7] The main endpoint is thrombus resolution at 3 months, checked first with echocardiography and then with MRI or cardiac CT if needed.^[7]

NCT03862859 studies the safety and efficacy of warfarin in people with atrial fibrillation on dialysis.^[8] It compares events such as transient ischemic attack, ischemic stroke, unspecified stroke, or death related to these events between warfarin and no treatment.^[8]

NCT05627375 looks at people with acute venous thromboembolism who are also taking antiplatelet therapy.^[9] The main outcome is clinically relevant bleeding during full-dose treatment, up to 12 months.^[9]

Table of Contents

• What is WT1 LAMP mRNA DC?
• How Does It Work?
• What Conditions Does It Treat?
• How Is It Administered?
• Current Clinical Trials
• Potential Benefits
• Possible Side Effects
• Conclusion

What is WT1 LAMP mRNA DC?

WT1 LAMP mRNA DC is an innovative immunotherapy treatment being studied for various types of cancer. It is a type of dendritic cell vaccine that uses the patient’s own immune cells to fight cancer^[1]. The name breaks down as follows:

• WT1: Stands for Wilms’ Tumor 1, a protein found in many types of cancer cells
• LAMP: Lysosome-Associated Membrane Protein, which helps the vaccine work more effectively
• mRNA: Messenger RNA, which carries instructions for making the WT1 protein
• DC: Dendritic Cells, a type of immune cell that helps activate the body’s cancer-fighting T cells

How Does It Work?

The WT1 LAMP mRNA DC vaccine works by stimulating the patient’s immune system to recognize and attack cancer cells. Here’s a simplified explanation of the process:

1. Doctors collect some of the patient’s blood cells through a process called leukapheresis^[2].
2. In the laboratory, these cells are transformed into dendritic cells and loaded with mRNA that instructs them to produce the WT1 protein.
3. The modified dendritic cells are then injected back into the patient.
4. Once in the body, these cells present the WT1 protein to the immune system, teaching it to recognize and attack cancer cells that express this protein.

What Conditions Does It Treat?

WT1 LAMP mRNA DC is being studied for several types of cancer, including:

• Glioblastoma: A type of aggressive brain cancer^[1]
• Malignant Pleural Mesothelioma: Cancer that affects the lining of the lungs^[2]
• High-Grade Glioma (HGG): Another type of brain cancer^[3]
• Diffuse Intrinsic Pontine Glioma (DIPG): A rare brain tumor that typically affects children^[3]

How Is It Administered?

WT1 LAMP mRNA DC is administered as a suspension for injection, typically given intradermally (into the skin)^[1]. The treatment is usually given in multiple doses over a period of time, often in combination with other cancer treatments like chemotherapy or radiation therapy.

Current Clinical Trials

Several clinical trials are currently underway to study the effectiveness and safety of WT1 LAMP mRNA DC in different cancer types:

• A study for newly diagnosed glioblastoma patients, combining the vaccine with standard chemotherapy (temozolomide)^[1]
• A trial for malignant pleural mesothelioma, combining the vaccine with chemotherapy and another immunotherapy drug called atezolizumab^[2]
• A study for children with high-grade glioma and diffuse intrinsic pontine glioma^[3]
• A trial for malignant pleural mesothelioma as a first-line treatment combined with standard chemotherapy^[4]

Potential Benefits

While research is still ongoing, WT1 LAMP mRNA DC shows promise in several areas:

• It’s a personalized treatment, using the patient’s own immune cells
• It may help improve survival rates and slow disease progression
• It can be combined with other cancer treatments for potentially better results
• It might have fewer side effects compared to traditional cancer treatments

Possible Side Effects

As with any medical treatment, WT1 LAMP mRNA DC may cause side effects. Based on the clinical trials, these may include:

• Local reactions at the injection site, such as redness or swelling
• Flu-like symptoms
• Fatigue

However, the full range of potential side effects is still being studied in clinical trials^[4].

Conclusion

WT1 LAMP mRNA DC represents an exciting development in cancer immunotherapy. While it’s still in the clinical trial phase, this personalized treatment approach offers hope for patients with difficult-to-treat cancers. As research continues, we may learn more about its effectiveness and potential applications in cancer treatment.

Table of Contents

• What is WT1 mRNA DC?
• Target Condition: Acute Myeloid Leukemia
• How WT1 mRNA DC Works
• Clinical Trial Details
• Eligibility Criteria
• Potential Benefits
• Administration and Treatment Duration

What is WT1 mRNA DC?

WT1 mRNA DC is an innovative vaccine being studied for the treatment of Acute Myeloid Leukemia (AML). This vaccine is a type of cell therapy, which means it uses cells from your own body to fight the disease.^[1]

The full name of this treatment is “Wilms’ tumor (WT1) antigen-targeted dendritic cell vaccination.” Let’s break this down:

• Wilms’ tumor (WT1): This refers to a specific protein found in many leukemia cells.
• Dendritic cells: These are special immune cells that help your body recognize and fight off harmful substances.
• Vaccination: Unlike traditional vaccines that prevent diseases, this is a therapeutic vaccine designed to treat an existing condition.

Target Condition: Acute Myeloid Leukemia

WT1 mRNA DC is being developed to treat Acute Myeloid Leukemia (AML). AML is a type of blood cancer that affects the bone marrow, where blood cells are made. In AML, abnormal white blood cells grow rapidly, interfering with the production of normal blood cells.^[1]

How WT1 mRNA DC Works

The WT1 mRNA DC vaccine works by stimulating your immune system to fight leukemia cells. Here’s a simplified explanation of the process:

1. Doctors collect some of your monocytes (a type of white blood cell).
2. These monocytes are transformed into dendritic cells in a laboratory.
3. The dendritic cells are then “loaded” with WT1 mRNA, which contains instructions for making the WT1 protein found on leukemia cells.
4. When injected back into your body, these modified dendritic cells help your immune system recognize and attack leukemia cells that have the WT1 protein.

This approach is known as immunotherapy because it uses your own immune system to fight the cancer.^[1]

Clinical Trial Details

WT1 mRNA DC is currently being studied in a Phase II clinical trial. This means that while it has shown promise in earlier studies, it is still considered experimental. The main goals of this trial are:

• To see if the vaccine can prevent AML from coming back (relapse) after initial treatment.
• To determine if it can help patients live longer overall.
• To check if it can reduce or eliminate any remaining cancer cells after standard treatment (known as minimal residual disease).
• To study how the vaccine affects patients’ immune systems and quality of life.^[1]

Eligibility Criteria

Not all AML patients are eligible for this trial. Some key criteria include:

• Being 18 years or older
• Having a high risk of AML relapse
• Having completed standard AML treatment and achieved remission
• Not being eligible for or choosing not to have a stem cell transplant

There are also several factors that might exclude a patient from participating, such as having certain other medical conditions or being pregnant.^[1]

Potential Benefits

While the effectiveness of WT1 mRNA DC is still being studied, researchers hope it may offer several benefits:

• Preventing or delaying AML relapse
• Improving overall survival
• Eliminating remaining cancer cells after standard treatment
• Enhancing quality of life for AML patients^[1]

Administration and Treatment Duration

WT1 mRNA DC is given as an intradermal injection, which means it’s injected just under the skin. The treatment period can last up to 97 days (about 3 months). The exact dosing schedule and amount may vary based on individual patient factors and will be determined by the healthcare team.^[1]

Table of Contents

• What is WT1/IL15/IL15RA mRNA DC?
• How Does It Work?
• Target Conditions
• Clinical Trial Details
• Eligibility Criteria
• Potential Benefits
• Safety and Side Effects

What is WT1/IL15/IL15RA mRNA DC?

WT1/IL15/IL15RA mRNA DC is an experimental cancer vaccine being studied for the treatment of advanced or refractory solid tumors^[1]. This innovative therapy belongs to a class of treatments called dendritic cell vaccines, which are designed to stimulate the body’s immune system to fight cancer cells^[2].

How Does It Work?

The vaccine is created using a patient’s own cells, making it a personalized treatment. Here’s a simplified explanation of how it works:

1. Doctors collect certain immune cells (monocytes) from the patient’s blood through a process called leukapheresis^[3].
2. These cells are then transformed into dendritic cells in the laboratory. Dendritic cells are important because they help activate other immune cells to recognize and attack cancer^[4].
3. The dendritic cells are then modified with special genetic instructions (mRNA) that tell them to produce three important components:
   • WT1 (Wilms’ Tumor 1): A protein often found in cancer cells^[5].
   • IL15 (Interleukin 15): A substance that helps stimulate immune cells^[6].
   • IL15RA (Interleukin 15 Receptor alpha): A component that helps IL15 work more effectively^[7].
4. The modified dendritic cells are then given back to the patient through an injection under the skin (intradermal injection)^[8].

Once in the body, these specially engineered cells are designed to activate the patient’s immune system to recognize and attack cancer cells that have the WT1 protein^[9].

Target Conditions

This experimental treatment is being studied for patients with advanced or refractory solid tumors, specifically in the following organs^[10]:

• Pancreas
• Esophagus
• Liver
• Ovaries

The treatment is intended for patients whose cancer has progressed after at least one previous treatment or for whom no standard therapy is available or suitable^[11].

Clinical Trial Details

The WT1/IL15/IL15RA mRNA DC vaccine is currently being studied in a Phase I/II clinical trial. This means it’s in the early stages of testing in humans^[12]. The main goals of this trial are:

1. To evaluate if it’s feasible to produce and administer the vaccine^[13].
2. To assess the safety of the treatment^[14].
3. To look for early signs of effectiveness against the cancer^[15].
4. To measure how well the vaccine stimulates the immune system^[16].
5. To understand how the treatment affects patients’ quality of life^[17].

Eligibility Criteria

Not all patients with the target cancers will be eligible for this trial. Some key eligibility criteria include^[18]:

• Age 18 or older
• Confirmed diagnosis of an advanced solid tumor in the pancreas, esophagus, liver, or ovaries
• Cancer that has progressed after at least one previous treatment, or no standard treatment options available
• Reasonable life expectancy of at least 3 months
• Good overall health status (WHO performance status 0-2)

Patients with certain conditions, such as autoimmune diseases or who are pregnant or breastfeeding, may not be eligible for the trial^[19].

Potential Benefits

While it’s important to remember that this is an experimental treatment and its effectiveness is not yet proven, the researchers hope to see the following potential benefits^[20]:

• Shrinkage or stabilization of tumors
• Longer time before the cancer progresses
• Improved overall survival
• Better quality of life for patients

Safety and Side Effects

As this is a new treatment, all possible side effects are not yet known. The clinical trial will closely monitor patients for any adverse events (side effects) that may occur during and after treatment^[21]. The safety of the vaccine is one of the main things being studied in this trial.

It’s important for patients to discuss potential risks and benefits with their healthcare team before considering participation in this or any clinical trial^[22].

Table of Contents

• Overview of the Voriconazole trials
• Conditions studied
• Study design, phases, and who can join
• Main outcomes being measured
• Trial-by-trial summary

Overview of the Voriconazole trials

The trial data show studies of Voriconazole in several serious fungal infections, including candidemia, invasive candidiasis, invasive mold infections, suspected invasive mould infection, and chronic pulmonary aspergillosis.^{[1][2][3][4][5]}

Most of the listed studies are Phase 3 trials, and one study is a Phase 2 trial.^{[1][2][3][4][5]}

Conditions studied

One study looks at chronic pulmonary aspergillosis, a long-lasting lung infection caused by Aspergillus, and it excludes people with single aspergilloma.^[1]

Two studies focus on candidemia and invasive candidiasis, which are serious Candida infections that can involve the bloodstream and other body sites.^[2][4]

Two studies focus on invasive mold infections or suspected invasive mould infection, which are serious infections caused by molds and may be treated quickly because they can become severe.^[3][5]

Study design, phases, and who can join

These are all interventional studies, which means the researchers give one or more treatments and compare the results.^{[1][2][3][4][5]}

The chronic pulmonary aspergillosis study is a prospective, randomized, single-blind study in non- or mildly-immunocompromised patients, meaning the researchers follow people forward in time, assign treatment by chance, and keep one side of the study unaware of the assignment.^[1]

The candidemia and invasive candidiasis studies include adults with uncomplicated disease or invasive disease, while the mold infection studies include adults with confirmed or suspected invasive mold infection.^[2][3][4][5]

Enrollment ranges from 80 people in the Phase 2 study to 399 people in one Phase 3 study.^[2][5]

Main outcomes being measured

The chronic pulmonary aspergillosis study measures therapeutic efficacy at 6 months, using both clinical improvement or stability and radiological improvement.^[1]

The candidemia study measures all-cause mortality at Day 28 after the first negative blood test, and it tests whether a shorter treatment course is not worse than a longer one by too much.^[2]

The invasive mold infection study measures all-cause mortality at Day 42.^[3]

The invasive candidiasis/candidemia study measures all-cause mortality at Day 30 and also checks for successful global response at end of treatment in the EU only.^[4]

The Phase 2 suspected invasive mould infection study measures all-cause mortality at Day 42 and also records serious adverse events and other treatment-emergent adverse events, including kidney, electrolyte, liver, infusion-related, photophobia, and photosensitivity events.^[5]

Trial-by-trial summary

NCT03656081 compares a six-month treatment plan in chronic pulmonary aspergillosis and looks at whether adding nebulised Ambisome® to itraconazole improves clinical and radiological results compared with itraconazole alone.^[1]

NCT06859671 studies short-duration therapy for uncomplicated candidemia and measures survival at Day 28 after the first negative blood culture.^[2]

2024-516216-16-00 studies adults with invasive mold infections caused by several mold types, including Aspergillus, Fusarium, Lomentospora prolificans, and Mucorales fungi, and measures Day 42 mortality.^[3]

NCT05178862 compares two treatment regimens for invasive candidiasis/candidemia and measures Day 30 mortality and global response at end of treatment.^[4]

2025-522835-32-00 is a Phase 2 study of early antifungal therapy for suspected invasive mould infection and measures survival and safety outcomes.^[5]

Table of Contents

• Overview of the Vericiguat trial program
• Heart failure studies in adults
• Studies in children with heart failure
• Studies in other conditions
• Trial design and main endpoints
• Who the trials are for

Overview of the Vericiguat trial program

The trial data show that Vericiguat is being tested in more than one disease area, with the main focus on heart failure.^[1][2] The studies include adults and children, and they use different trial phases, mainly Phase 2 and Phase 3, with one Phase 4 study listed.^[1][2]

Several studies are completed, while others are authorised, which means they are planned or allowed to start.^[1][2] The trials are designed to look at both benefit and safety, depending on the condition being studied.^[1][2]

Heart failure studies in adults

Most of the studies in this set focus on heart failure with reduced ejection fraction (HFrEF) or related forms of heart failure.^[1][3] In one large Phase 3 trial, researchers compared Vericiguat with placebo in 6,836 participants with chronic HFrEF and measured the time to the first event of cardiovascular death or heart failure hospitalization.^[3]

Another completed Phase 3 study in 17 participants with HFrEF and a CardioMEMS HF System looked at the lowering of diastolic pulmonary artery pressure (dPAP) compared with placebo.^[1] This is a pressure measure in the blood vessels that carry blood from the heart to the lungs.^[1]

A Phase 2 study in 138 participants with chronic HFrEF examined whether starting Vericiguat at 5 mg was tolerated over two weeks.^[4] The main safety questions were whether participants could finish the 5 mg dose and whether they had moderate to severe symptomatic hypotension, which means low blood pressure causing symptoms such as dizziness or fainting.^[4]

Studies in children with heart failure

Two trials focus on pediatric participants with heart failure due to left ventricular systolic dysfunction.^[2][5] One is a Phase 4 randomized, placebo-controlled, double-blind study with 320 participants, and it looks at change in NT-proBNP from baseline to Week 16 in the base period, plus safety in the extension period.^[2]

The open-label extension study included 254 participants and was designed to monitor safety and tolerability of Vericiguat.^[5] In an open-label study, everyone knows what treatment is being given.^[5]

Studies in other conditions

Not all of the studies are in heart failure. One Phase 2 trial in 21 participants with treatment-resistant hypertension is testing Vericiguat as part of a combination approach and measuring change in systolic blood pressure by 24-hour ambulatory blood pressure monitoring.^[6]

Another Phase 2 study in 55 participants with unequivocal epicardial and/or microvascular vasospastic angina is examining microvascular function and daily angina episodes.^[7] This study uses placebo and compares 10-week treatment periods to see whether symptoms and blood vessel function change.^[7]

A completed Phase 2 study also looked at Vericiguat in participants with post-COVID-19 syndrome, with or without chronic fatigue syndrome criteria, and measured physical function using the SF-36 physical function score over 10 weeks.^[8]

Trial design and main endpoints

Several studies use a randomized, double-blind, and placebo-controlled design, which helps make the comparison fair.^[1][2][3] In these designs, participants are assigned by chance, neither the participants nor the study team know who gets the active treatment, and placebo is used as the comparison treatment.^[1][2]

The main endpoints vary by trial. They include cardiovascular death, heart failure hospitalization, NT-proBNP change, dPAP lowering, treatment tolerability, safety events, blood pressure change, angina frequency, microvascular conductance, and physical function scores.^{[1][2][3][4][6][7][8]}

Some studies also track adverse events, which are unwanted medical problems that happen during a trial, and discontinuation due to adverse events.^[2][5] This helps researchers understand not only whether the treatment may help, but also how well it is tolerated in the study group.^[2][5]

Who the trials are for

The target groups in these trials include adults with chronic HFrEF, children with heart failure due to left ventricular systolic dysfunction, people with treatment-resistant hypertension, people with documented vasospastic angina, and people with post-COVID-19 syndrome.^{[1][2][3][6][7][8]}

The studies are not all the same size: some are small, such as the 17-participant and 21-participant studies, while others are much larger, such as the 6,836-participant heart failure trial.^[1][3][6] This mix of sizes suggests that researchers are testing different questions, from early signals to larger outcome studies.^[1][3][6]

Table of Contents

• Trial overview
• Primary localised prostate cancer study
• Scar prevention study
• Outcomes and measures
• Who may participate
• What the results may mean

Trial overview

The source data include two interventional studies, which means researchers give a planned treatment and then measure the results.^[1][2] One study is in people with primary localised prostate cancer, and the other is in people with surgical wounds to study scar prevention.^[1][2] Both studies are listed as Authorised.^[1][2]

Primary localised prostate cancer study

The first trial is an open-label Phase 1 study of the SpectraCure P18 System and verteporfin for injection in men with primary localised prostate cancer.^[1] Open-label means that people in the study and the research team know what treatment is being given.^[1] The study is designed for patients with organ-confined prostate cancer diagnosed within the last 9 months.^[1]

The brief summary says the main goal is to show that this approach is safe for patients with organ-confined prostate cancer and to find the safe maximum light threshold dose, starting at 20 J/cm2.^[1] A dose escalation plan is used, which means the treatment setting is increased step by step to find a safe level.^[1]

Scar prevention study

The second trial, called SCARFREE-001: Verteporfin for Scar Prevention, is a Phase 2 study.^[2] It is looking at whether intradermal VERTEPORFIN, meaning injection into the skin, can help prevent scars after surgery.^[2] The study includes scar formation following surgical wounds and compares VERTEPORFIN with saline, which is a placebo treatment used for comparison.^[2]

The study tests three doses of VERTEPORFIN: 0.5, 1.0, and 2.0 mg/mL.^[2] The goal is to learn whether there is a dose-response effect, which means whether higher or different doses change the result in a predictable way.^[2]

Outcomes and measures

In the prostate cancer study, the main outcome is safety, measured by toxicity using CTCAE v5.0 and by MRI checks for severe damage to the tissues around the prostate.^[1] The study also looks for no Grade 3 toxicity in the rectum or bladder and no drug-related serious adverse events as a sign of success.^[1]

In the scar prevention study, the main outcome is scar quality at 3 months.^[2] Researchers compare the three VERTEPORFIN doses with placebo in both sutured incision segments and punch biopsy wounds using the Observer part of the Patient and Observer Scar Assessment Scale, or POSAS.^[2]

Who may participate

Based on the trial data, the prostate cancer study is for people with newly diagnosed, localised disease that is still confined to the prostate and was diagnosed within the past 9 months.^[1] The scar prevention study is for people who have surgical wounds, including closed wounds and open punch biopsy wounds.^[2]

The trial records provided do not list every inclusion or exclusion rule, so the full eligibility details are not known from the source data alone.^[1][2]

What the results may mean

These trials are early steps in understanding whether VERTEPORFIN can be used in very different medical settings.^[1][2] In prostate cancer, the focus is on safety and tissue protection around the treatment area.^[1] In wound care, the focus is on whether VERTEPORFIN may improve the look and quality of scars after surgery.^[2]

Because one study is Phase 1 and the other is Phase 2, the data are still early and are mainly meant to guide future research rather than give final answers.^[1][2]

Table of Contents

• Clinical trials overview
• Conditions and patient groups
• Trial phases and study designs
• What is being measured
• Selected trials with Vancomycin
• What the trial results mean for patients

Clinical trials overview

These studies investigate Vancomycin in many different research settings, mostly for infections and infection prevention.^[1][2] The trials ask questions about whether Vancomycin works, how safe it is in the study setting, and how it compares with other treatments or placebo.^[3][4]

Some studies use Vancomycin alone, while others use it together with other antibiotics or as part of a larger treatment strategy.^[5][6] A few trials also study Vancomycin in prevention settings, such as before surgery or during transplantation care.^[7][8]

Conditions and patient groups

The trial data include people with Staphylococcus aureus bacteremia, which means bacteria are present in the blood.^[9] Other studies involve periprosthetic joint infection, pyogenic vertebral osteomyelitis (bone infection in the spine), pleural infections, and infections linked to surgery or implanted material.^[10][11][12]

Vancomycin is also studied in people with Clostridioides difficile infection, primary sclerosing cholangitis, active ulcerative colitis, and patients with resistant bacteria such as VRE and MDR Enterobacteriaceae.^[13][14][15] The target groups include adults, children, critically ill patients, surgical patients, and patients hospitalized for stem cell transplantation.^[16][17]

Trial phases and study designs

The studies cover Phase 1, Phase 2, Phase 3, and one low-intervention trial.^[18] Phase 1 studies in the source data focus on drug levels in cerebrospinal fluid or early safety and feasibility in children.^[19][20]

Phase 2 trials look at early effectiveness, safety, and biological effects, such as recurrence of infection, drug response, or changes in the gut microbiome.^[21][22] Phase 3 trials are larger and often compare Vancomycin with standard care, placebo, or another treatment to test whether one approach is non-inferior, meaning not worse than the other by a set margin.^[23][24]

What is being measured

The main outcomes include clinical cure, recurrence, treatment failure, and mortality.^[25][26] Some trials also measure whether patients need more antibiotics, surgery, or hospital readmission after the first treatment period.^[27][28]

Several studies measure drug levels in blood or cerebrospinal fluid, which helps researchers understand exposure to the treatment in the body.^[29][30] Other endpoints include quality of life, health costs, microbiome changes, and laboratory measures such as ALP, which is alkaline phosphatase, a liver-related blood test used in one study.^[31][32]

Selected trials with Vancomycin

NCT05137119 is a large Phase 3 platform trial in patients with Staphylococcus aureus bacteremia. It measures all-cause mortality at 90 days and includes Vancomycin among several treatment options.^[9]

2023-507617-96-01 studies pyogenic vertebral osteomyelitis and asks whether early switch to oral antibiotics after one week of IV treatment is non-inferior to longer IV treatment. Vancomycin is one of the IV options in the study.^[10]

NCT05256693 tests oral Vancomycin to prevent Clostridioides difficile infection in people hospitalized for allogeneic hematopoietic stem cell transplantation, with infection during hospitalization as the main outcome.^[13]

NCT05876182 compares oral Vancomycin with placebo in adults and young patients with Primary Sclerosing Cholangitis, using ALP levels at 6 months as the main endpoint.^[14]

NCT04731025 studies local antibiotics, including Vancomycin, in women having implant-based breast reconstruction, with implant loss within 180 days as the main outcome.^[33]

2024-515791-12-00 is a completed Phase 1 study in children with external ventricular drain that measured Vancomycin levels in cerebrospinal fluid, including Cmax, tmax, AUC0-τ, and half-life.^[19]

What the trial results mean for patients

When a trial measures non-inferiority, it is testing whether a shorter or simpler treatment is not meaningfully worse than the standard approach.^[23] This matters in studies of infections where shorter treatment could reduce time in hospital or reduce treatment burden if the results are good enough.^[24]

When a study looks at microbiome changes, it is studying how treatment may affect the normal germs in the gut.^[15] When it measures quality of life or QALYs, it is trying to understand how treatment affects daily life and overall health value, not only infection control.^[31]

Overall, the trial program shows that Vancomycin is being studied across many different patient groups, from children to adults, and across both treatment and prevention settings.^[1][16] The main focus is whether it helps control infection, prevent recurrence, and do so with acceptable safety and practical benefit.^[3][25]

Table of Contents

• Trial overview
• Who is being studied
• What the trial measures
• Trial design and phase
• Trial status and size
• Important patient terms

Trial overview

The trial with NCT ID 2024-520132-15-00 is an interventional study that is authorised and plans to include 240 participants.^[1] It is studying patients undergoing vitrectomy and/or cataract surgery, and the brief summary says the study aims to investigate the effect of music on perioperative pain and the effect of herbal medicine on perioperative pain.^[1]

Who is being studied

The target population is patients undergoing vitrectomy and/or cataract surgery.^[1] These are eye surgery patients who are having retrobulbar anaesthesia, which is a numbing procedure used for the operation.^[1]

The trial compares oral interventions listed as Nervenruh forte – Dragees and Bromazepam Genericon 3 mg Filmtabletten, with the herbal medicine focus stated in the brief summary.^[1] The source data does not give more detail about who can or cannot join beyond the surgery type.^[1]

What the trial measures

The main endpoint is the NRS-P score 30 seconds after the retrobulbar block.^[1] An endpoint is the main result a study wants to measure, and in this trial it is used to check pain soon after the anaesthetic block.^[1]

The brief summary also says the study aims to investigate perioperative pain, and the title mentions perioperative anxiety and pain.^[1] This means the researchers are interested in how patients feel around the time of surgery, especially pain and nervousness.^[1]

Trial design and phase

This is an interventional study, which means the researchers are giving or comparing treatments as part of the study.^[1] The phase is listed as Low Intervention, meaning the trial involves only limited extra intervention beyond usual care.^[1]

The source data does not provide a classic drug development phase such as Phase 1, Phase 2, or Phase 3.^[1] Instead, it uses the Low Intervention label, which is the phase-like category reported for this study.^[1]

Trial status and size

The study status is Authorised, so it has been approved to proceed.^[1] The planned enrollment is 240 participants, which gives an idea of the study size.^[1]

Because the trial is focused on eye surgery patients, the results may help show whether the study approach changes pain after retrobulbar anaesthesia in this setting.^[1] The data provided does not include final results, so the article can only describe what the trial is designed to study.^[1]

Important patient terms

Vitrectomy is an eye operation, and cataract surgery is surgery to treat a cloudy lens in the eye.^[1] Retrobulbar anaesthesia is a way to numb the eye area for surgery.^[1]

Perioperative means the time around surgery, including before and after the operation.^[1] Anxiety means worry or nervousness, and pain is the unpleasant feeling the study is trying to measure.^[1]

Table of Contents

• Overview of the Valganciclovir trials
• Cancer studies
• CMV and transplant studies
• Heart surgery study
• Trial phases and study designs
• Main outcomes being measured
• Who can participate

Overview of the Valganciclovir trials

These clinical trials are testing Valganciclovir in several very different patient groups, not as a general medicine review but as a study treatment in specific research settings.^{[1][2][3][4][5][6]}

The trial data show research in EBV-positive relapsed/refractory lymphomas, CMV prevention after kidney transplant, CMV management after major heart surgery, CMV prevention in renal recipients at high risk after transplant, CMV treatment in kidney transplant recipients, and newly diagnosed glioblastoma.^{[1][2][3][4][5][6]}

Cancer studies

One Phase 2 trial, called NAVAL-1, studied Valganciclovir together with nanatinostat in patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas.^[1]

The main goal was to evaluate anti-tumor activity, which means whether the treatment helped shrink or control the cancer.^[1]

The primary outcome was objective response rate (ORR), measured by an Independent Review Committee using the 2007 International Working Group criteria.^[1]

Another Phase 2 trial studied Valganciclovir in people with newly diagnosed glioblastoma, with less than 1 cm3 of contrast-enhancing tumor left after surgery.^[6]

This study compared standard therapy plus Valganciclovir against standard therapy without it, using a placebo tablet for comparison.^[6]

The main endpoint was overall survival, measured from surgery until death from any cause, with the final analysis planned when the last patient reached 30 months of follow-up.^[6]

CMV and transplant studies

Several Phase 3 trials focused on CMV, which stands for cytomegalovirus.^[2][3][4][5]

In the CYTOPREV study, kidney transplant patients were studied to compare an immuno-guided prevention strategy with a universal prophylactic strategy, and the main outcome was the proportion of patients with CMV infection within 6 months after transplantation.^[2]

In another Phase 3 study, renal recipients at high risk of post-transplant CMV were studied, and the main endpoint was whether CMV infection or disease occurred within 6 months after transplant.^[4]

A third Phase 3 study tested letermovir plus Valganciclovir against Valganciclovir alone in kidney transplant recipients with CMV infection.^[5]

Its main outcome was virological response at Week 3, meaning a major drop in CMV DNA in the blood or no detectable CMV DNA below the study cutoff.^[5]

Heart surgery study

The GAN-CAR trial was a Phase 3 multicenter, double-blind, randomized clinical trial in high-risk immunocompetent adults after major heart surgery.^[3]

It studied targeted pre-emptive antiviral therapy for patients who had stayed at least 3 days in the cardiac surgery ICU and had CMV viral load.^[3]

The primary outcome was the number of days with a good outcome during 30 days of follow-up, where a good outcome meant the patient was alive, out of the ICU, not needing systemic antimicrobials, not on mechanical ventilation, and without serious adverse events.^[3]

Trial phases and study designs

The trial set includes both Phase 2 and Phase 3 studies, showing that Valganciclovir is being tested in both earlier and later stages of clinical research.^{[1][2][3][4][5][6]}

Some trials are interventional, which means the researchers assign a treatment strategy and then measure results.^{[1][2][3][4][5][6]}

One study used a combination treatment with nanatinostat, while another used Valganciclovir with letermovir, and some studies compared Valganciclovir with placebo or with different prevention strategies.^[1][5][6]

Main outcomes being measured

The studies measure different endpoints depending on the disease being treated.^{[1][2][3][4][5][6]}

• Objective response rate in lymphoma, which shows how many patients had a measurable cancer response.^[1]

• CMV infection within 6 months after kidney transplant, used to test prevention strategies.^[2][4]

• Good outcome days after heart surgery, which captures recovery and serious illness in the first 30 days.^[3]

• Virological response at Week 3 in kidney transplant recipients with CMV infection, based on CMV DNA levels in blood.^[5]

• Overall survival in glioblastoma, measured from surgery until death from any cause.^[6]

Who can participate

Each study has a different target population, so eligibility depends on the condition being studied.^{[1][2][3][4][5][6]}

People in these trials include patients with EBV-positive relapsed or refractory lymphomas, kidney transplant recipients, renal recipients at high risk of CMV, immunocompetent adults after major heart surgery, and newly diagnosed glioblastoma patients with very small remaining tumor after surgery.^{[1][2][3][4][5][6]}

The enrollment sizes range from 30 to 502 participants, showing that some studies are small and focused, while others include larger groups.^{[1][2][3][4][5][6]}

Table of contents

• Clinical trials overview
• Trials in atopic dermatitis and eczema
• Trial in dry foot skin with diabetes
• What the trials measure
• Who the trials are for
• Trial phases and status

Clinical trials overview

The clinical trial data for Urea focuses on moisturiser studies in skin disease, not on general drug use.^[1][2][3][4] The main conditions studied are atopic dermatitis, also called eczema, and xerotic skin on the feet in people with diabetes.^[1][3] These are interventional studies, which means researchers give a treatment and compare results across groups.^[1][2]

Trials in atopic dermatitis and eczema

Two trials studied moisturiser treatment for atopic dermatitis, one in children and one in adults.^[1][2] The child study was a Phase 3 trial with 270 participants and aimed to show that a newly developed moisturiser could better prevent eczema relapse than a reference cream.^[1] In this study, relapse meant a return of eczema that the child, parent, or legal guardian felt needed stronger treatment, and the date of relapse was recorded in an eDiary and confirmed by the investigator.^[1]

The adult study was a Phase 2 trial with 55 participants and tested whether a new moisturiser, Propyduo®, could strengthen the skin barrier better than no treatment and better than Propyless® over 4 weeks.^[2] The brief summary says the study included adults with a history of atopic dermatitis.^[2] This trial helps show whether a moisturiser can improve skin barrier function in people who have had eczema before.^[2]

A later authorised Phase 2 trial is also studying maintenance treatment for atopic dermatitis in 78 participants.^[4] It compares Oviderm cream with a Urea/propylene glycol cream and looks at time to relapse of eczema during the maintenance phase.^[4] The outcome is patient-reported, meaning the person in the study reports when the eczema comes back.^[4]

Trial in dry foot skin with diabetes

One authorised Phase 3 trial studies creams for dry foot skin in people with diabetes.^[3] The condition is described as xerotic skin on the foot of subjects with diabetes, and the study compares Oviderm with Canoderm 5% cream.^[3] The goal is to show that the test product is better than the comparator in reducing xerosis, which means very dry skin, after 4 weeks of treatment.^[3]

What the trials measure

The main outcome in the child eczema trial is relapse of atopic eczema, measured as a hazard ratio.^[1] A hazard ratio compares how often an event happens in one group versus another over time.^[1] In the adult skin-barrier trial, the main measure is Trans Epidermal Water Loss (TEWL), which shows how much water escapes through the skin.^[2] Lower water loss usually suggests a stronger skin barrier, so this test helps researchers compare the creams.^[2]

The diabetes foot study uses the Xerosis Severity Scale to judge how dry the skin is before and after treatment.^[3] The maintenance eczema study measures time to relapse of eczema from baseline until relapse or the end of the maintenance phase, whichever comes first.^[4] These endpoints show whether the creams help people stay stable for longer or improve dryness and barrier function.^[1][2][3][4]

Who the trials are for

The target groups differ by trial, but all are focused on skin problems where moisturising treatment may help.^[1][2][3][4] One study is for children with atopic dermatitis, another for adults with a history of atopic dermatitis, and another for people with diabetes who have dry feet.^[1][2][3] The authorised maintenance trial also includes people with atopic dermatitis.^[4]

• Children with eczema: The goal is to see if a moisturiser can keep eczema from coming back.^[1]

• Adults with past eczema: The goal is to see if a moisturiser improves the skin barrier after 4 weeks.^[2]

• People with diabetes and dry feet: The goal is to see if a cream can reduce very dry skin on the feet.^[3]

• People in maintenance treatment: The goal is to see how long eczema stays away during ongoing care.^[4]

Trial phases and status

The trial data includes Phase 2 and Phase 3 studies.^[1][2][3][4] Phase 2 studies are usually smaller and look for early signs that a treatment may work, while Phase 3 studies are larger and compare treatments more directly.^[1][2][3][4] Two studies are completed, and two are authorised.^[1][2][3][4]

The completed studies include the Phase 3 child eczema relapse trial and the Phase 2 adult skin-barrier trial.^[1][2] The authorised studies include the Phase 3 diabetes foot dryness trial and the Phase 2 maintenance eczema trial.^[3][4] Enrollment ranged from 55 to 270 in the studies with reported numbers, showing that the trials vary in size depending on the research question.^[1][2][4]

Table of contents

• Trial overview
• Conditions studied
• Who the studies include
• Trial phases and study design
• Main endpoints and what they mean
• Special study types and comparisons
• Pediatric studies

Trial overview

The trial data show that Ustekinumab is being studied in many interventional clinical trials, mostly in Phase 3 and some in Phase 2 or long-term safety settings.^[1] These studies are authorised or completed and focus on diseases where the immune system plays a major role.^[1]

The main purpose of these trials is to measure whether treatment strategies that include Ustekinumab can improve disease control, reduce symptoms, and support remission in adults and children.^[1]

Conditions studied

Ustekinumab trials in the data include psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, juvenile psoriatic arthritis, and folliculitis decalvans.^[1] Some studies focus on active disease, while others focus on stable disease, long-term follow-up, or disease that came back after earlier treatment or surgery.^[1]

Several trials also study inflammatory bowel disease in special situations, such as after bowel surgery or after loss of response to earlier Ustekinumab treatment.^[1]

Who the studies include

The target populations are mostly adults with active or moderate to severe disease, but some studies are designed for children and teenagers aged 2 to under 18 years or 6 to under 18 years.^[1] Some trials include people who are biologic-naïve, meaning they have not used biologic treatment before, while others include patients who already tried other treatments and still have active disease.^[1]

Other trials include people with stable minimal disease activity, people with refractory disease, meaning disease that is hard to treat, and patients with Crohn’s disease who had surgery and have risk factors for recurrence.^[1]

Trial phases and study design

Most studies are Phase 3 trials, which are larger studies that compare treatment effects and safety in more patients.^[1] The data also include Phase 2 studies, which are earlier studies that look for a first signal of benefit and collect safety information.^[1]

Some studies are open-label, meaning everyone knows the treatment being used, and some are randomised, meaning participants are assigned to groups by chance.^[1] There is also a low-intervention long-term safety study and an open-label extension study, which follows patients for a longer time after earlier trials.^[1]

Main endpoints and what they mean

The trials measure different endpoints, or study results, depending on the disease.^[1] In psoriatic arthritis, one study measures minimal disease activity and PASDAS at 12 months, while another measures ACR 20 response at Week 16.^[1]

In Crohn’s disease and ulcerative colitis, common endpoints include clinical remission, endoscopic remission, corticosteroid-free remission, and changes in scores such as CDAI, SES-CD, and PRO-2.^[1] In psoriasis studies, common endpoints include PASI 90, PASI 75, and IGA 0/1, which show how much the skin improved.^[1]

Some studies also measure safety outcomes, such as adverse events, serious adverse events, laboratory tests, injection-site reactions, and treatment changes because of loss of response.^[1]

Special study types and comparisons

Several trials compare Ustekinumab with other advanced therapies such as infliximab, vedolizumab, risankizumab, guselkumab, deucravacitinib, and other biologic or targeted treatments.^[1] Some studies test whether combination therapy works better than Ustekinumab alone, especially in Crohn’s disease and ulcerative colitis.^[1]

Other studies use Ustekinumab as an active control, which means it is the standard treatment used for comparison against a newer medicine.^[1] A few studies also look at therapeutic drug monitoring, which means measuring drug levels to guide treatment decisions.^[1]

Pediatric studies

Some of the most important Ustekinumab trials in the data are pediatric studies for children and teenagers with moderate to severe plaque psoriasis, moderately to severely active Crohn’s disease, moderately to severely active ulcerative colitis, and juvenile psoriatic arthritis.^[1] These studies look at both efficacy and safety, and some also measure pharmacokinetics, which means how the body handles the treatment over time.^[1]

Long-term extension studies in pediatric participants are also included to collect safety data over time and to follow patients who had already been in earlier clinical studies.^[1]

Table of Contents

• Clinical trials overview
• What each study is testing
• Who takes part in these trials
• Trial phases and study size
• Main endpoints and results measured
• Important terms used in the trials

Clinical trials overview

The trial data show Tropicamide being used in eye research for pupil dilation, which means making the pupil larger for an eye exam or surgery.^[2][4] In these studies, Tropicamide appears in trials for pre-operative use, diagnostic use, and as part of study procedures in eye disease research.^[2][1][3][6]

The studies are interventional, which means the researchers give a treatment or procedure and then measure the effect.^{[1][2][3][4][5][6]} The listed trials are in Phase 1, Phase 2, Phase 3, and Phase 1/2.^{[1][2][3][4][5][6]}

What each study is testing

One Phase 1 study tested a fixed-dose combination of 0.34% Tropicamide and 2.5% phenylephrine hydrochloride for pupil dilation, and compared it with Mydriasert.^[2] The main goal was to see the change in pupil diameter at 60 minutes after the first dose.^[2]

A Phase 2 study in adults with atopic keratoconjunctivitis included Tropicamide as part of the eye-drop procedures while testing Isocyclosporin A against vehicle.^[1] Its main endpoint was the mean change in ocular itching score from baseline to Week 4.^[1]

Another Phase 2 study in dry eye disease also included Tropicamide in the study procedures while testing different concentrations of rhNGF eye drops against vehicle.^[3] The main endpoint was the mean change in dry eye symptoms from baseline to Week 8 using the SANDE Global Score.^[3]

A Phase 3 study in children with cataract examined Mydrane for eye injection during surgery, with the goal of giving enough pupil dilation so surgery could be done without mechanical dilation.^[4] This study focused on both safety and effectiveness in children.^[4]

In a Phase 1/2 study in retinitis pigmentosa, Tropicamide was among the eye medicines used in the study setting while researchers assessed the safety of a unilateral subretinal administration of HORA PDE6B.^[5] The safety checks included eye examinations, inflammation, chorioretinal tolerance, questionnaires, vital signs, and laboratory measurements.^[5]

A Phase 3 study in persistent corneal epithelial defect included Tropicamide among the study eye drops while evaluating cenegermin versus vehicle.^[6] The main endpoint was complete epithelial healing at Week 4, with the result needing to stay present at Week 8.^[6]

Who takes part in these trials

The patient groups are different across the studies, showing that Tropicamide appears in several eye research settings.^{[1][2][3][4][5][6]}

• Adults with atopic keratoconjunctivitis took part in the Phase 2 study of Isocyclosporin A eye drops.^[1]

• People needing pre-operative mydriasis or diagnostic dilation took part in the Phase 1 Tropicamide and phenylephrine study.^[2]

• Patients with dry eye disease were included in the Phase 2 rhNGF study.^[3]

• Children having cataract surgery were studied in the Mykid study of Mydrane.^[4]

• Patients with retinitis pigmentosa carrying PDE6B gene mutations were enrolled in the Phase 1/2 HORA PDE6B study.^[5]

• Patients with persistent corneal epithelial defect were included in the Phase 3 cenegermin study.^[6]

Trial phases and study size

The studies cover several stages of research, from early testing to later confirmation work.^{[1][2][3][4][5][6]}

Main endpoints and results measured

The trials measure different outcomes depending on the study goal.^{[1][2][3][4][5][6]}

• Ocular itching score was measured in the atopic keratoconjunctivitis study using a visual analogue scale, which is a simple line-based symptom score.^[1]

• Pupil diameter at 60 minutes was the main result in the Tropicamide and phenylephrine study.^[2]

• Dry eye symptom score was measured with SANDE Global Score at Week 8 in the dry eye study.^[3]

• Sufficient pupillary dilatation for surgery was the key result in the pediatric cataract study.^[4]

• Safety parameters in the retinitis pigmentosa study included eye exam findings, inflammation, chorioretinal tolerance, questionnaires, vital signs, and laboratory tests.^[5]

• Complete epithelial healing at Week 4, maintained at Week 8, was the main endpoint in the PCED study.^[6]

Important terms used in the trials

Vehicle means the comparison product without the active study drug, used to see whether the tested treatment works better.^[1][3][6] Baseline means the starting point before treatment begins.^[1][2][3]

Chorioretinal tolerance means how well the retina and the layer under it can tolerate the treatment.^[5] Mechanical dilation means using a tool to enlarge the pupil if eye drops do not dilate it enough.^[4]

Table of Contents

• Trial overview
• Target populations
• Study phases and designs
• Main endpoints being measured
• What the trials compare
• Study status and enrollment

Trial overview

The provided trial records do not describe a direct clinical trial of Tryptophan. Instead, they list interventional studies in heart surgery, organ transplantation, hemodialysis, and nutrition support.^[1][2][3]

These studies are designed to compare two treatment strategies, often to see whether one is as good as, or safer than, another.^[1][4]

Target populations

One trial studies adults having major cardiac surgery with extracorporeal circulation, which means surgery using a heart-lung machine.^[1]

Two trials focus on children: one in pediatric heart transplantation and one in children with congenital heart malformation, which means a heart problem present at birth.^[2][5]

Other trials include people undergoing liver, kidney, or kidney-pancreas transplantation, patients after oesophagectomy, patients after major emergency abdominal surgery, and adults on chronic hemodialysis.^[3][6][7][8]

Study phases and designs

The trial list includes both Phase 2 and Phase 3 studies.^[1][2][3]

Phase 2 studies in the list are the pediatric heart transplantation study and the pediatric congenital heart surgery study, and both are focused on safety and early performance signals.^[2][5]

Most of the remaining studies are Phase 3 trials, which usually compare treatments in larger groups and look for stronger evidence about effect and safety.^[1][3][4]

Several studies are described as randomized and single-blind, meaning treatment assignment is by chance and one side of the study does not know which treatment is given.^[2][5][4]

Main endpoints being measured

The heart surgery trial measures a combined outcome of death, perioperative AMI, low cardiac output needing ionotropics, and AKIN-III acute kidney failure at 90 days.^[1]

Here, AMI means acute myocardial infarction, or heart attack, and AKIN-III means severe acute kidney injury.^[1]

The pediatric heart transplantation study measures safety through continuous adverse event reporting for up to 3 months.^[2]

The liver transplantation study measures the area under the curve of GPT, also called ALT, during the first 7 days after transplantation.^[3]

The pediatric congenital heart surgery study measures safety through adverse event reporting up to 30 days after surgery and heart muscle protection through CK-MB levels up to day 7 or discharge.^[5]

The hemodialysis study measures the difference in myofibrillar fractional synthetic rate during one week, which is a marker of muscle protein building.^[4]

The oesophagectomy study measures muscle size on CT scan before and 10 days after surgery.^[6]

The emergency abdominal surgery study measures the rate of infectious complications during the hospital stay.^[7]

The kidney, liver, and kidney-pancreas transplantation study measures delayed graft function for kidney transplants and AUC of GPT (ALT) for liver transplants over the first 7 days.^[8]

What the trials compare

The cardiac surgery trial compares Custodiol crystalloid cardioplegia with Buckberg hematic cardioplegia, with a goal of showing that Custodiol is not worse than the blood-based method by a clinically important amount.^[1]

The pediatric heart transplantation trial compares Custodiol with Custodiol-N for organ perfusion, which means preserving the organ before transplant.^[2]

The liver transplantation study also compares Custodiol with Custodiol-N and looks at liver injury after transplant through ALT results.^[3]

The hemodialysis study looks at the effect of IDPN, which is intradialytic parenteral nutrition, meaning nutrition given through a vein during dialysis.^[4]

The pediatric congenital heart surgery study compares Custodiol-N with Custodiol for cardioplegia, and the trial is focused on safety and heart muscle protection.^[5]

The transplantation study covering kidney, liver, and kidney-pancreas surgery compares Custodiol-N with Custodiol for graft preservation, meaning keeping the transplanted organ in good condition.^[8]

Study status and enrollment

Most of the listed studies are Authorised, which means they are approved to run.^{[1][2][3][4][6][7][8]}

One pediatric cardiac surgery trial is Suspended, which means it has been paused.^[5]

Enrollment ranges from 15 participants in the small pediatric heart transplantation study to 600 participants in the large cardiac surgery trial.^[2][1]

This mix of small and large studies suggests that the research questions range from early safety testing to broader comparison of treatment results in real patient groups.^[2][8]

Table of contents

• Overview of Trimethoprim trials
• Urinary tract and kidney-related infection studies
• Bloodstream and serious infection studies
• Bone, joint, and implant infection studies
• Special patient groups and prevention studies
• Main endpoints used in the trials

Overview of Trimethoprim trials

The trial data show Trimethoprim mainly as part of Sulfamethoxazole and Trimethoprim, used in studies of infection treatment, step-down therapy, and prevention.^[1] Most studies are Phase 3 trials, with some Phase 2 studies and one Phase 1 transplant study.^[2] The studies include adults, children, transplant recipients, and people with serious bacterial infections or urinary tract problems.^[3]

Several trials compare shorter treatment with longer treatment, or oral treatment with intravenous treatment.^[4] Other trials study prevention of infection after surgery, after transplant, or in people with repeated infections.^[5]

Urinary tract and kidney-related infection studies

Many Trimethoprim-related trials focus on urinary tract infection (UTI), which means infection in the urinary system.^[6] One Phase 3 trial studies children 1 month to 3 years old with acute pyelonephritis, a kidney infection, and compares 3 days of intravenous antibiotics followed by 7 days of oral antibiotics with 3 days of intravenous treatment alone.^[7] The main outcome is recurrence of febrile UTI within 28 days after treatment ends.^[7]

Another Phase 3 trial studies kidney transplant recipients with pyelonephritis and tests whether 7 days of treatment is not worse than 14 days of treatment.^[8] Its main result is clinical cure at day 30, defined as fever below 38°C and no UTI symptoms, with no extra antibiotic treatment needed.^[8] A separate Phase 3 trial studies women with recurrent urinary tract infections and compares methenamine hippurate with antibiotic prevention, including SEPTRIN, which contains Trimethoprim in the source data.^[9]

Trimethoprim also appears in studies of febrile UTI in adults and in children with posterior urethral valves, a urinary condition that can affect bladder drainage.^[10] These studies look at clinical response, time to first infection, and whether antibiotic strategies can reduce infection risk.^[10]

Bloodstream and serious infection studies

Some trials study serious infections in hospitalized patients, where Trimethoprim is used as part of a treatment option.^[11] One Phase 3 study in adults with Gram-negative bacteraemia compares early switch to oral fluoroquinolones or Trimethoprim-sulfamethoxazole with continued intravenous therapy.^[12] The main endpoint is 30-day all-cause mortality.^[12]

Another Phase 3 trial studies short-course treatment for Gram-negative bacteremia with a urinary source in hospitalized, immunocompetent adults.^[13] Its main outcome is 90-day survival without clinical or microbiological failure.^[13] In catheter-related bloodstream infection due to Staphylococcus aureus, Trimethoprim-sulfamethoxazole is one of several treatments being compared, and the main outcome is clinical cure without relapse at day 30.^[14]

Trimethoprim is also part of a Phase 3 trial in severe anti-GBM antibody disease, also called Goodpasture disease, where the main result is kidney function at 6 months measured by eGFR, which means estimated glomerular filtration rate, a test of how well the kidneys filter blood.^[15]

Bone, joint, and implant infection studies

Several trials use Trimethoprim-related regimens in bone and joint infections.^[16] One Phase 3 study in prosthetic joint infection compares treatment strategies and includes Cotrimoxazol, which contains Trimethoprim in the source data.^[17] Its main outcome is treatment success 15 months after surgery, defined by no infection-related re-surgery, no new antibiotic treatment for the same joint, no ongoing antibiotics at the end of follow-up, and no death.^[17]

Another Phase 3 trial studies infections of osteosynthesis material after long bone fractures.^[18] This trial checks whether a shorter antibiotic course works as well as a longer one after surgical treatment with implant retention or removal.^[18] The main outcome is clinical failure, including return of symptoms, need to stop or change antibiotics, and fracture healing measures.^[18]

A Phase 3 study in diabetic foot osteomyelitis also includes Cotrim forte, which contains Trimethoprim in the source data.^[19] The main outcome is healed ulcer or osteomyelitis resolution at 12 and 24 weeks, with no further antimicrobial treatment and stable wound closure.^[19]

Special patient groups and prevention studies

Trimethoprim appears in trials involving special patient groups, including children with cancer, transplant recipients, and people with immune-related conditions.^[20] One Phase 1 kidney transplant study evaluates the safety of Treg02, a cell therapy, and includes Cotrim-ratiopharm in the background treatment list.^[21] The trial measures acute toxicity, over-suppression of the immune system, chronic toxicity, and biopsy-confirmed acute rejection within 60 weeks.^[21]

A Phase 1 study in children with malignant brain tumors measures antibiotic concentrations in cerebrospinal fluid, the fluid around the brain and spinal cord.^[22] This study includes Eusaprim, which contains Trimethoprim in the source data, and measures pharmacokinetic parameters, meaning how the body absorbs and moves the drug.^[22]

Another Phase 3 study in adults undergoing allogeneic blood and marrow transplant includes Bactrim in the control regimen and measures fungal-free survival at day 90.^[23] In hematology and cancer-related studies, Trimethoprim-containing prophylaxis is also used alongside other supportive treatments to help prevent infections during intensive therapy.^[24]

Main endpoints used in the trials

The trials use several types of endpoints, or main results, depending on the condition being studied.^[25] Common endpoints include clinical cure, symptom resolution, recurrence of infection, treatment failure, mortality, and kidney function.^[26] Some trials also measure antibiotic exposure in the blood, microbiological clearance, quality of life, or safety events such as serious adverse events.^[27]

For patient safety, some studies focus on whether treatment causes serious side effects or whether immune suppression, infection, or rejection occurs in transplant patients.^[21] In other studies, the main goal is not to prove a new treatment is better, but to show that a shorter or simpler treatment is not worse than the standard approach.^[4]

Table of contents

• Trial overview
• Who can participate
• What is being measured
• Study design and status
• Patient terms explained

Trial overview

The available trial investigates TROCKENEXTRAKT AUS PASSIONSBLUMENKRAUT 5-7:1, AUSZUGSMITTEL ETHANOL 60 % (V/V) in the setting of eye surgery.^[1] Its brief summary says the study aims to investigate the effect of music on perioperative pain and the effect of herbal medicine on perioperative pain.^[1]

The trial is titled “The effect of music on perioperative anxiety and pain of patients undergoing retrobulbar anaesthesia.”^[1] This tells us the research is centered on anxiety and pain around the time of surgery, not on long-term disease treatment.^[1]

Who can participate

The study includes patients undergoing vitrectomy and/or cataract surgery.^[1] These are eye operations, so the target population is people scheduled for these procedures.^[1]

The trial data do not list any other eligibility details, such as age limits or extra medical conditions.^[1] Based on the source, the main known group is patients having eye surgery with retrobulbar anaesthesia.^[1]

What is being measured

The main endpoint is the NRS-P score 30 seconds after the retrobulbar block.^[1] An endpoint is the main result a trial measures to see whether the study question is answered.^[1]

NRS-P is a pain rating score, so this trial is checking how much pain patients feel very soon after the block.^[1] The trial also looks at perioperative anxiety and pain more broadly, based on the study title and summary.^[1]

Study design and status

The study is listed as Interventional and Low Intervention.^[1] Interventional means the researchers are testing a planned approach in participants, while Low Intervention suggests a lower-burden study design.^[1]

The status is Authorised, and the planned enrollment is 240 participants.^[1] Enrollment means the number of people the study aims to include.^[1]

Patient terms explained

Perioperative anxiety means worry or nervousness before, during, or after surgery.^[1] Perioperative pain means pain linked to the surgery period.^[1]

A retrobulbar block is an injection used around the eye to numb it for surgery.^[1] The study checks the pain score shortly after this block to understand the immediate patient experience.^[1]

Vitrectomy and cataract surgery are eye operations, and both are part of the study population described in the trial record.^[1] The source does not provide more detail on outcomes beyond the pain score and the anxiety/pain focus.^[1]

Table of contents

• Trial overview
• Who is being studied
• What is being compared
• Study phase and design
• Main outcome being measured
• What the results may mean

Trial overview

The available trial data show one authorised study of TROFOLASTAT in people with prostate cancer.^[1] This study is called PROSTAMIP and is a comparative, prospective, randomized trial for primary prostate cancer staging.^[1]

The study is looking at whether the experimental imaging arm can detect local lymph node metastases better than the control arm.^[1] In simple terms, the researchers want to know which scan is better at finding cancer spread to nearby lymph nodes.^[1]

Who is being studied

The trial targets people with prostate cancer who need imaging for staging.^[1] Staging means checking how far the cancer has spread in the body.^[1]

The planned enrollment is 320 participants.^[1] This size allows the researchers to compare the imaging groups in a larger patient group.^[1]

What is being compared

The study compares three imaging-related options listed in the trial data: 18F-PSMA-1007, Pylclari, and 99mTc-MIP-1404.^[1] The brief summary says the experimental arm uses 99mTc-MIP-1404 SPECT/CT, while the control arm uses ce-wbCT.^[1]

SPECT/CT is an imaging test that combines two scan methods to help show where disease may be found.^[1] The trial is testing whether the experimental scan gives better staging information than the control scan.^[1]

Study phase and design

This is a Phase 4 study.^[1] Phase 4 studies are later-stage trials, often used to compare how a test performs in clinical practice.^[1]

The study type is interventional, which means the researchers assign participants to study groups rather than only observing them.^[1] The title also says the trial is prospective and randomized, meaning people are followed forward in time and placed into groups by chance.^[1]

Main outcome being measured

The primary outcome is the proportion of subjects with local lymph node metastases in the control and experimental arms, as read by the study readers.^[1] A primary outcome is the main result the trial is designed to measure.^[1]

This outcome is important because it shows how often each imaging method finds nearby lymph node spread.^[1] The brief summary states that the experimental arm is expected to be superior in detecting these metastases compared with the control arm.^[1]

What the results may mean

If the experimental imaging approach finds more local lymph node metastases, it may help doctors stage prostate cancer more accurately.^[1] Better staging can support more informed treatment planning because it gives a clearer picture of disease spread.^[1]

At this stage, the trial data only describe the study aim and design, not final results.^[1] So the main focus is on comparing imaging performance in prostate cancer, not on treatment outcomes.^[1]

Table of Contents

• What is TREG02?
• How Does TREG02 Work?
• Clinical Trial Details
• Who Can Participate in the TREG02 Trial?
• Potential Benefits of TREG02
• Safety Considerations
• Conclusion

What is TREG02?

TREG02 is a new medical treatment being studied for patients who have received a kidney transplant. It is classified as an Advanced Therapy Medicinal Product (ATMP), which means it’s a cutting-edge treatment that uses biological materials from the patient’s own body^[1]. Specifically, TREG02 is a solution for injection that contains regulatory T cells, also known as Tregs.

How Does TREG02 Work?

TREG02 works by using the patient’s own regulatory T cells, which are a type of immune cell that helps control the immune system’s response. In the context of kidney transplants, these cells are specially prepared and then given back to the patient. The goal is to help the patient’s body accept the new kidney without rejecting it, potentially reducing the need for other immunosuppressive drugs^[1].

Clinical Trial Details

The clinical trial for TREG02 is called “ProTreg” and is currently in Phase I/IIa. This means it’s in the early stages of testing in humans. The main objectives of this trial are to:

1. Determine if TREG02 is safe for kidney transplant recipients
2. Investigate if TREG02 can help the body accept the transplanted kidney
3. Gather initial data on whether TREG02 could allow for a reduction in other immunosuppressive medications

This trial is specifically for patients who have received a kidney from a deceased donor^[1].

Who Can Participate in the TREG02 Trial?

The trial has specific criteria for who can participate. Some key points include:

• Patients aged 18-65 with severe kidney disease (GFR < 15 ml/min x 1.73 m²)
• Patients who are about to receive a kidney transplant from a deceased donor
• Patients who have not had any previous organ transplants
• Patients without certain health conditions like HIV, hepatitis, or cancer

There are many other specific criteria that doctors will use to determine if someone is eligible for the trial^[1].

Potential Benefits of TREG02

While it’s important to remember that TREG02 is still in the testing phase, researchers hope it could offer several benefits:

• Reduced risk of the body rejecting the transplanted kidney
• Potential to decrease the amount of other immunosuppressive drugs needed
• Improved long-term outcomes for kidney transplant patients

The trial will measure these potential benefits in various ways, including monitoring for signs of kidney rejection and assessing kidney function over time^[1].

Safety Considerations

As with any new medical treatment, safety is a top priority. The trial will closely monitor patients for any side effects or complications. Some specific areas of focus include:

• Immediate reactions to the TREG02 injection
• Signs of over-suppression of the immune system, which could increase the risk of infections
• Long-term effects, such as the potential development of autoimmune disorders or certain types of cancer

It’s important to note that these are potential risks that the researchers will be watching for, not confirmed side effects of TREG02^[1].

Conclusion

TREG02 represents an exciting new approach to helping kidney transplant patients. By using the body’s own regulatory T cells, it aims to improve transplant outcomes and potentially reduce the need for other immunosuppressive drugs. However, it’s still in the early stages of testing, and more research is needed to fully understand its effects and benefits. If you’re a kidney transplant patient and are interested in learning more about TREG02, talk to your doctor about whether you might be eligible for this or similar clinical trials.

Table of Contents

• Clinical trials overview
• Who the trials include
• Trial phases and study designs
• Main outcomes being measured
• Conditions being studied
• Important patient terms

Clinical trials overview

These trials study Tremelimumab in many cancer settings, often together with durvalumab and sometimes with surgery, radiation, chemotherapy, or other local treatments.^[1][2][3] The main purpose is to see whether these treatment plans are safe and whether they help control cancer better than the comparison treatment or usual care.^[1][4]

Several studies are already Authorised, and some are Completed.^[1][3] The trials cover both earlier and later stages of research, so the questions range from basic safety and feasibility to survival and cancer control.^[5][6]

Who the trials include

The studies include many different patient groups, depending on the cancer type and treatment goal.^[1][7] Some trials include adults with advanced or unresectable cancer, such as advanced hepatocellular carcinoma, metastatic urothelial cancer, or unresectable malignant mesothelioma.^[4][8][9]

Other trials focus on people whose cancer can still be removed with surgery, such as resectable gastric cancer, oral cavity cancer, or resectable hepatocellular carcinoma.^[10][11][12] A few studies also include children and young adults with advanced solid tumors.^[13]

Some trials are limited to special clinical situations, such as patients who have not had prior systemic therapy, people with microsatellite instability, or patients with cancer that has not progressed after chemoradiation.^[2][10][14]

Trial phases and study designs

Most of the Tremelimumab studies in the source data are Phase 2 or Phase 3 trials.^[1][4][6] Phase 2 trials usually look at early signs that the treatment works, while Phase 3 trials compare treatments in larger groups and focus on stronger proof of benefit.^[4][6]

There are also Phase 1 studies, which mainly check safety, feasibility, and early biological effects.^[5][11] For example, one Phase 1 study tests bronchoscopic injection of Tremelimumab in early-stage non-small cell lung cancer, and another Phase 1 study in children and young adults looks at safety and dose-finding.^[11][13]

Some studies are randomized, which means patients are assigned by chance to different treatment groups.^[4][8] Others are open-label, meaning both the research team and the patient know which treatment is being given.^[4]

Main outcomes being measured

The most common outcome is overall survival, which means how long patients live after randomization or study start.^[4][8][15] Several large studies in hepatocellular carcinoma, urothelial cancer, lung cancer, and mesothelioma use this as a main endpoint.^[4][8][15]

Other important outcomes include progression-free survival, which measures how long the cancer stays under control, and objective response rate, which shows how many patients have a meaningful tumor shrinkage on scans.^[6][9][10] Some studies also measure recurrence-free survival, disease-free survival, or event-free survival, which are ways to track whether the cancer returns or gets worse after treatment.^[1][12][16]

Safety is also a major endpoint in many trials, including counts of adverse events, serious adverse events, dose-limiting toxicities, and treatment stopping because of side effects.^[1][5][12] Some trials add detailed tests such as scans, lab tests, ECGs, vital signs, pathology review, or tumor tissue markers like CD8 infiltration and ctDNA status.^[1][10][11]

Conditions being studied

Hepatocellular carcinoma is the most common cancer type in the trial list, with several studies testing Tremelimumab in advanced, locoregional, intermediate-stage, resectable, unresectable, or high-burden disease.^{[4][6][16][17]} These trials examine different treatment settings, including first-line therapy, perioperative treatment, and combinations with TACE, SIRT, ablation, or hepatic arterial infusion.^[6][16][17]

Bladder and urinary tract cancers are also studied, including muscle-invasive bladder cancer and unresectable locally advanced or metastatic urothelial cancer.^[1][8] In these studies, Tremelimumab is tested with durvalumab and sometimes with chemotherapy or surgery, with survival and event-free survival as key outcomes.^[1][8]

Other cancers in the source data include cholangiocarcinoma and biliary tract cancer, non-small cell lung cancer, small-cell lung cancer, renal cell carcinoma, malignant mesothelioma, gastric cancer, squamous cell carcinoma of the oral cavity, colorectal cancer, endometrial cancer, and several metastatic squamous cancers treated with radiotherapy.^{[2][5][9][10][11][13][14][18]}

Important patient terms

Neoadjuvant therapy means treatment given before surgery, often to shrink the tumor or make surgery more effective.^[2][10] Adjuvant therapy means treatment given after surgery to lower the chance that cancer returns.^[12]

Resectable means the tumor can be removed by surgery, while unresectable means surgery cannot remove it completely or safely.^[4][9] Metastatic means the cancer has spread to other parts of the body.^[5][7]

Microsatellite instability is a tumor feature used to select some patients for the gastric cancer study, and ctDNA means circulating tumor DNA, a blood test that can help track cancer after treatment.^[10] RECIST and mRECIST are scan-based rules used to measure how tumors respond to treatment.^[6][10]

Table of Contents

• Trial overview
• Pain and musculoskeletal studies
• Ear and eye studies
• Skin and soft tissue studies
• Pediatric and surgical studies
• What the trials measure
• Who the trials include

Trial overview

These studies are testing Triamcinolone Acetonide in different clinical settings, not as a general drug description but as a study treatment in specific patient groups.^[1]

Most of the trials in the source data are Phase 3 studies, with a smaller number of Phase 2 studies and one low-intervention trial.^[1][2]

The trials are mostly interventional studies, which means the research team assigns a treatment or procedure and then measures the results.^[1]

Pain and musculoskeletal studies

Several trials study pain and movement problems, including fibromyalgia-related trapezius pain, frozen shoulder, chronic shoulder pain, rheumatoid arthritis, and thumb base osteoarthritis.^[1]

In the fibromyalgia study, researchers compare regional treatment for trapezius pain using bupivacaine and Triamcinolone Acetonide versus saline or placebo, and the main outcome is pain on the Visual Analogue Scale at weeks 2, 4, and 12.^[1]

In frozen shoulder, the study compares physical therapy, corticosteroid injection, and the combination of both, with the Shoulder Pain and Disability Index as the main result.^[1]

For chronic shoulder pain, one trial compares corticosteroid nerve block with pulsed radiofrequency and uses SPADI to measure pain and disability.^[1]

The rheumatoid arthritis trials look at whether corticosteroid bridging or a tailored treatment plan can help patients reach remission or lower disease activity, using measures such as DAS28-CRP and disease activity over time.^[1]

The thumb joint osteoarthritis study measures pain during daily activities after 4 and 12 weeks to see whether steroid injections work better than saline or occupational therapy.^[1]

Ear and eye studies

One Phase 2 study looks at persistent sudden sensorineural hearing loss and tests intracochlear Triamcinolone Acetonide, which means the treatment is placed inside the cochlea, the hearing part of the inner ear.^[1]

The main outcome in that study is the change in hearing threshold on day 30, measured in the frequencies most affected by hearing loss.^[1]

Other studies in the source data involve eye-related conditions such as postoperative recovery after vitrectomy and geographic atrophy, where Triamcinolone Acetonide appears as part of the treatment or control setup.^[1]

In the vitrectomy study, the main question is whether NSAID eye drops reduce the risk of increased eye pressure compared with steroid eye drops after surgery.^[1]

In geographic atrophy studies, the main outcomes include change in lesion area and long-term safety and tolerability, with retinal imaging and eye examinations used for follow-up.^[1]

Skin and soft tissue studies

Some trials focus on skin disease and painful scar tissue, including hidradenitis suppurativa, atopic dermatitis, and post-surgical scar pain.^[1]

In hidradenitis suppurativa, Triamcinolone Acetonide is used as an intralesional treatment in Phase 3 studies that compare treatment plans and measure HiSCR50 at week 16.^[1]

HiSCR50 means at least a 50% drop in abscess and inflammatory nodule count, without more draining tunnels or fistulae than at the start of the study.^[1]

For post-surgical scar pain, one Phase 3 study compares botulinum toxin with corticosteroid injection and uses the Numerical Rating Scale for pain as the main outcome.^[1]

In the atopic dermatitis study in children and adolescents, Triamcinolone Acetonide appears as a cutaneous treatment option alongside other treatments in a large Phase 3 trial that also measures skin improvement and drug exposure data.^[1]

Pediatric and surgical studies

Some studies include children, such as the trial on strictures after esophageal atresia repair, where local steroid injections are tested to see whether they can reduce the number of dilatations needed over time.^[1]

That study is a low-intervention trial and focuses on the number of dilatations needed within 28-day intervals up to 6 months after the study procedure.^[1]

Other studies include adolescents and adults, such as the birch pollen allergy trial and the atopic dermatitis trial, showing that the age range changes based on the condition being studied.^[1]

The carpal tunnel syndrome study compares an injection-first strategy with surgery-first care and measures success after one year using the Boston Carpal Tunnel Questionnaire symptom score.^[1]

What the trials measure

The main outcomes vary by disease, but they often focus on patient-reported symptoms, function, or disease control.^[1]

• Pain scores: Several studies use pain scales such as VAS or NRS to see whether symptoms improve after treatment.^[1]

• Function scores: Trials in shoulder and hand disease use tools like SPADI or the Boston Carpal Tunnel Questionnaire to measure daily function and symptom burden.^[1]

• Hearing outcomes: The hearing loss study measures change in hearing threshold using audiometry, which is a hearing test.^[1]

• Disease control: Rheumatoid arthritis and hidradenitis suppurativa studies measure remission or response rates to show whether the condition is getting better.^[1]

• Safety: Some trials measure adverse events, lab tests, eye pressure, or other safety checks to understand how well the treatment is tolerated in the study setting.^[1]

Who the trials include

The target populations are different across studies and include adults with rheumatoid arthritis, adults with shoulder or hand pain, children with esophageal strictures, adolescents and adults with allergy or skin disease, and patients with sudden hearing loss.^[1]

Some studies require a very specific diagnosis, such as persistent sudden sensorineural hearing loss after unsuccessful conservative therapy, unilateral Menière’s disease, or fibromyalgia with trapezius myofascial pain.^[1]

Other studies include broader groups, such as people with hidradenitis suppurativa, atopic dermatitis, or rheumatoid arthritis according to 2010 criteria.^[1]

Overall, the trial data show that Triamcinolone Acetonide is being studied in many different patient groups, with each trial designed around one main health problem and one main outcome.^[1]

Table of Contents

• What are Medium Chain Triglycerides (MCTs)?
• Medical Uses of MCTs
• Benefits of MCTs
• Administration and Dosage
• Potential Side Effects and Precautions
• Ongoing Research

What are Medium Chain Triglycerides (MCTs)?

Medium Chain Triglycerides, commonly known as MCTs, are a type of fat with unique properties that make them valuable in medical treatments. MCTs are composed of fatty acids with a chain length of 6 to 12 carbon atoms^[1]. They are different from long-chain triglycerides (LCTs) found in most dietary fats because they are more easily absorbed and metabolized by the body.

MCTs are often derived from vegetable sources and can be found in products like coconut oil and palm kernel oil. In medical settings, they are usually administered as part of specialized nutritional formulations.

Medical Uses of MCTs

Medium Chain Triglycerides have several important medical applications:

• Parenteral Nutrition: MCTs are a key component in parenteral nutrition formulations, which are used to provide nutrition to patients who cannot eat by mouth. These formulations, such as SmofKabiven and Medialipide, contain MCTs along with other nutrients to support patients’ nutritional needs^[2].
• Malabsorption Disorders: MCTs can be beneficial for patients with conditions that affect fat absorption, such as pancreatic insufficiency or short bowel syndrome. The shorter chain length of MCTs allows for easier absorption in the intestines.
• Ketogenic Diets: MCTs are sometimes used in ketogenic diets for epilepsy management, as they can be converted to ketones more easily than other fats.
• Cachexia: In some cases, MCTs may be used to help combat cachexia, a condition of extreme weight loss and muscle wasting often associated with chronic diseases.

Benefits of MCTs

The unique properties of Medium Chain Triglycerides offer several benefits in medical treatments:

• Rapid Energy Source: MCTs are quickly absorbed and metabolized, providing a rapid source of energy for patients who may have difficulty processing other types of fats.
• Improved Nutrient Absorption: In patients with malabsorption issues, MCTs can help improve the absorption of fat-soluble vitamins and other nutrients.
• Reduced Fat Storage: Unlike long-chain triglycerides, MCTs are less likely to be stored as body fat, which can be beneficial for patients at risk of excessive weight gain.
• Ketone Production: MCTs can be converted to ketones, which may provide an alternative energy source for the brain and other organs.

Administration and Dosage

MCTs are typically administered as part of specialized nutritional formulations. In clinical settings, they may be given through intravenous infusion. For example, in one study, patients received an intravenous infusion of 0.11 g lipid/kg/hour of a 20% MCT emulsion during a 4-hour hemodialysis session^[3].

The dosage and administration method can vary depending on the specific medical condition and the patient’s needs. It’s crucial that MCT administration is overseen by healthcare professionals to ensure proper dosing and monitoring.

Potential Side Effects and Precautions

While MCTs are generally well-tolerated, there are some potential side effects and precautions to be aware of:

• Gastrointestinal Distress: Some patients may experience nausea, vomiting, or diarrhea, especially when MCTs are first introduced.
• Allergic Reactions: Patients with allergies to coconut, palm kernel, or soy products should use MCT products with caution.
• Liver Function: In patients with liver disease, MCT metabolism may be affected, requiring careful monitoring.
• Ketoacidosis Risk: In rare cases, excessive use of MCTs could potentially lead to ketoacidosis, particularly in patients with diabetes.

It’s important to note that MCT administration should always be under medical supervision, especially in clinical settings such as during hemodialysis or parenteral nutrition.

Ongoing Research

Research into the medical applications of MCTs is ongoing. Current studies are exploring their potential benefits in various areas:

• Hemodialysis: One study is investigating whether infusion of MCTs during hemodialysis can improve the clearance of certain toxins in patients with chronic kidney disease^[3].
• Muscle Wasting: Another study is examining how the route of nutrition, including MCT-containing formulations, affects muscle wasting in patients recovering from esophageal surgery^[4].
• Neonatal Care: MCTs are also being studied as part of nutritional support for preterm infants^[5].

These ongoing studies highlight the potential for MCTs to play an increasingly important role in various medical treatments and nutritional support strategies.

Table of Contents

• What is Trabectedin?
• What Conditions Does Trabectedin Treat?
• How Does Trabectedin Work?
• How is Trabectedin Administered?
• Clinical Trials and Research
• Potential Side Effects
• Effectiveness of Trabectedin

What is Trabectedin?

Trabectedin, also known by its brand names Yondelis, ET-743, or IMLYGIC, is a chemotherapy drug used to treat certain types of cancers^[1][2]. It is derived from a marine organism and belongs to a class of drugs called alkylating agents, which work by damaging the DNA of cancer cells to stop them from growing and dividing^[3].

What Conditions Does Trabectedin Treat?

Trabectedin is primarily used to treat the following conditions:

• Soft Tissue Sarcomas: These are rare cancers that develop in the body’s soft tissues, such as muscles, tendons, and fat^[1][2].
• Liposarcoma and Leiomyosarcoma: Specific types of soft tissue sarcomas that Trabectedin has shown effectiveness against^[3].
• Advanced Breast Cancer: Some studies have explored the use of Trabectedin in patients with advanced breast cancer^[4].
• Prostate Cancer: Research has been conducted on the potential use of Trabectedin in advanced prostate cancer^[5][6].
• Pediatric Solid Tumors: Some clinical trials have investigated the use of Trabectedin in children with refractory (resistant to treatment) solid tumors^[7].
• Pancreatic Cancer: Studies have explored the use of Trabectedin in metastatic pancreatic cancer after first-line chemotherapy^[8].

How Does Trabectedin Work?

Trabectedin works by interfering with the DNA of cancer cells. It binds to the DNA, causing damage and preventing the cells from dividing and growing. This action can lead to the death of cancer cells or stop them from spreading further^[3]. Additionally, some research suggests that Trabectedin may also affect the tumor microenvironment, which is the area surrounding the cancer cells, potentially enhancing its anti-cancer effects^[1].

How is Trabectedin Administered?

Trabectedin is typically administered as an intravenous (IV) infusion, which means it is given directly into a vein. The specific dosage and schedule can vary depending on the condition being treated and the individual patient. Some common administration methods include:

• A 24-hour infusion every 3 weeks^[2]
• A 3-hour infusion weekly for 3 weeks, followed by a week of rest^[4]
• Doses ranging from 1.0 to 1.5 mg/m² (milligrams per square meter of body surface area)^[1][6]

Trabectedin is often given through a central venous catheter, which is a special tube placed into a large vein for easier administration of medications^[4]. Patients may also receive other medications, such as dexamethasone, before Trabectedin to help manage potential side effects^[6].

Clinical Trials and Research

Numerous clinical trials have been conducted to evaluate the effectiveness and safety of Trabectedin in various cancer types. These trials have explored different dosing regimens, combination therapies, and potential biomarkers that might predict treatment response^[1][2][3]. Some notable areas of research include:

• Combining Trabectedin with other cancer treatments, such as immunotherapy drugs (e.g., Ipilimumab and Nivolumab)^[1]
• Investigating the effectiveness of Trabectedin in specific soft tissue sarcoma subtypes^[9]
• Exploring the use of Trabectedin in patients who are not suitable for standard chemotherapy regimens^[2]
• Studying the impact of Trabectedin on the tumor microenvironment and immune cell trafficking^[1]

Potential Side Effects

Like all cancer treatments, Trabectedin can cause side effects. The severity and types of side effects can vary from person to person. Some potential side effects include:

• Fatigue
• Nausea and vomiting
• Decreased blood cell counts (which can increase the risk of infection, anemia, or bleeding)
• Liver function abnormalities
• Muscle and joint pain

It’s important to discuss potential side effects with your healthcare team, as they can provide guidance on managing these effects and may adjust your treatment if necessary^[2][9].

Effectiveness of Trabectedin

The effectiveness of Trabectedin can vary depending on the type of cancer and individual patient factors. In clinical trials, Trabectedin has shown promising results in certain soft tissue sarcomas, particularly liposarcoma and leiomyosarcoma^[3]. Some key points about its effectiveness include:

• Trabectedin has been shown to improve progression-free survival (the time during which the cancer does not worsen) in some patients with soft tissue sarcomas^[2][9].
• Response rates (the percentage of patients whose cancer shrinks or disappears after treatment) vary but are generally modest, often around 10-30%^[4][6].
• Some patients experience stable disease, meaning their cancer neither grows nor shrinks significantly, which can be considered a positive outcome in advanced cancers^[2].
• Research is ongoing to identify which patients are most likely to benefit from Trabectedin and how to optimize its use in combination with other treatments^[1][9].

It’s important to remember that the effectiveness of any cancer treatment, including Trabectedin, can vary greatly from person to person. Your oncologist is the best source of information about how this treatment might work for your specific situation.

Table of Contents

• What is Tramadol Hydrochloride?
• Uses of Tramadol
• Different Formulations
• How Tramadol Works
• Dosage and Administration
• Effectiveness in Pain Management
• Potential Side Effects
• Precautions and Considerations

What is Tramadol Hydrochloride?

Tramadol Hydrochloride, also known simply as Tramadol HCl, is a prescription medication used to treat moderate to severe pain^[1]. It belongs to a class of drugs called opioid analgesics, which work by changing how your brain perceives and responds to pain^[2]. Tramadol is sometimes referred to by the brand name Ultracet when combined with acetaminophen (also known as paracetamol)^[3].

Uses of Tramadol

Tramadol is primarily used to manage various types of pain, including:

• Postoperative pain: Pain experienced after surgical procedures^[4]
• Acute pain: Sudden onset pain, such as from injuries^[4]
• Low back pain: Pain in the lower region of the spine^[5]
• Shoulder pain: Pain in the shoulder area^[5]
• Neck pain: Pain in the neck region^[5]

It’s important to note that tramadol is typically prescribed when other pain medications, such as over-the-counter options, have not been effective in managing pain.

Different Formulations

Tramadol comes in various formulations to suit different needs:

• Immediate Release (IR) tablets: These release the medication quickly into your system^[2]
• Extended Release (ER) or Once-A-Day (OAD) tablets: These release the medication slowly over time, allowing for less frequent dosing^[2]
• Combination tablets: Tramadol is sometimes combined with acetaminophen for enhanced pain relief^[3]

How Tramadol Works

Tramadol works in two ways to relieve pain:

1. It binds to opioid receptors in the brain, changing how your body perceives pain.
2. It increases levels of certain neurotransmitters (chemical messengers) in the brain, particularly serotonin and norepinephrine, which can help reduce pain signals^[2].

When tramadol enters your body, it is converted into an active metabolite called O-desmethyltramadol, which contributes to its pain-relieving effects^[6].

Dosage and Administration

The dosage of tramadol can vary depending on the formulation and individual patient needs. Some common dosages include:

• Immediate Release tablets: 50 mg every 4-6 hours as needed^[2]
• Extended Release tablets: 100 mg, 200 mg, or 300 mg once daily^[6]
• Combination tablets (with acetaminophen): Usually contain 37.5 mg tramadol and 325 mg acetaminophen^[3]

It’s crucial to take tramadol exactly as prescribed by your healthcare provider. Do not adjust your dose without consulting your doctor first.

Effectiveness in Pain Management

Clinical studies have shown that tramadol can be effective in managing various types of pain. For example:

• In postoperative pain management, tramadol combined with acetaminophen has shown to provide significant pain relief^[4]
• For acute neck, shoulder, and low back pain, tramadol with acetaminophen has demonstrated effectiveness in reducing pain intensity^[5]

The effectiveness of tramadol can be measured using various scales, such as the Numeric Rating Scale (NRS) for pain intensity and the Patient Global Impression of Change (PGIC) for overall improvement^[4][5].

Potential Side Effects

Like all medications, tramadol can cause side effects. Common side effects may include:

• Nausea
• Dizziness
• Constipation
• Headache
• Drowsiness

More serious side effects, though rare, can occur. It’s important to contact your healthcare provider if you experience any unusual or severe side effects^[1].

Precautions and Considerations

When taking tramadol, keep the following in mind:

• Tramadol can be habit-forming, especially with long-term use. Use it only as directed by your doctor.
• Do not drink alcohol while taking tramadol, as it can increase the risk of serious side effects.
• Inform your doctor about all other medications you’re taking, as tramadol can interact with many other drugs.
• If you need to use tramadol for an extended period, your doctor may need to adjust your dosage or switch you to a different pain management strategy^[2].

Always consult with your healthcare provider for personalized advice and information about tramadol use.